New application of PEG-phospholipid molecule

By using PEG-phospholipid molecules to form an artificial layer on the surface of cells such as red blood cells and platelets, the problem of antibody binding to cell surface antigens in emergency situations has been solved, achieving the effects of inhibiting agglutination and AMR, simplifying the treatment process and extending the success rate of organ transplantation.

CN118900913APending Publication Date: 2024-11-05ICOAT MEDICAL AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380025695.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-08-12
Filing Date
2023-03-07
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

In emergency situations where complete crossmatching is not possible during blood transfusions or organ transplants, existing technologies struggle to effectively inhibit the binding of antibodies to cell surface antigens such as red blood cells and platelets, leading to agglutination or antibody-mediated rejection (AMR). Furthermore, traditional methods are time-consuming and cumbersome.

Method used

Poly(ethylene glycol) phospholipids (PEG-phospholipids) molecules are used to form a transient, non-toxic artificial layer on the cell surface. The phospholipid domains are anchored to the cell membrane through hydrophobic interactions, selectively masking surface antigens and preventing antibody binding.

Benefits of technology

It effectively inhibits the binding of antibodies to cell surface antigens, reduces the risk of agglutination and AMR, simplifies the handling process in emergency situations, and continuously inhibits the release of cytokines after organ transplantation, reducing the occurrence of AMR.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900913A_ABST
    Figure CN118900913A_ABST
Patent Text Reader

Abstract

The present invention relates to the selective masking of surface antigens on red blood cells, platelets and / or endothelial cells using PEG-phospholipid molecules. Thus, blood products treated with PEG-phospholipid molecules can be infused into non-cross-matched or incompatible receptors and reduce the risk of binding and agglutinating antibodies to the surface antigens. Accordingly, organ grafts treated with PEG-phospholipid molecules can be transplanted into non-cross-matched or incompatible receptors and reduce the risk of antibody binding and antibody-mediated rejection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to poly(ethylene glycol) phospholipid (PEG-phospholipid) molecules and their use in selectively masking cell surface antigens. Background Art

[0002] Donor-recipient testing, also called cross-matching or crossmatching, is a test performed as part of blood compatibility testing before a blood transfusion. Typically, this involves adding the recipient's plasma to a sample of red blood cells from the donor. If the donor's blood is incompatible with the recipient's blood, antibodies in the recipient's blood will bind to antigens on the donor's red blood cells. This antibody-antigen reaction can cause the red blood cells to clump (so-called agglutination) or be destroyed.

[0003] In addition to blood typing of the donor and recipient and screening for unexpected blood group antibodies, crossmatching is one of a series of steps in a series of pre-transfusion testing. The complete crossmatching process takes up to 1 hour and is therefore not always used in emergency situations. In such emergency situations, patients who do not have pre-formed antibodies may be given Rh-O negative blood. However, this type of blood is rare and not available in large quantities.

[0004] ABO crossmatching and complement-dependent cytotoxicity (CDC) assays are also used to determine compatibility between donors and recipients in organ transplants, where pre-existing anti-ABO or anti-class I human leukocyte antigen (HLA) antibodies may be present. If the recipient has received multiple transfusions or has had children, there is a risk of immunization against one or more of the more than 50 blood group antigens. Such pre-existing antibodies, called irregular antibodies, make it difficult to select compatible blood. In addition, pre-existing anti-ABO and anti-class I HLA antibodies may also result in reduced circulation time for platelets transfused to the patient to prevent bleeding due to thrombocytopenia.

[0005] WO 2004 / 050897 discloses a method for preparing an RBC composition having reduced antigenicity and reduced hemolysis levels. The method involves the reaction of an activated antigen masking compound having a molecular weight of about 20-40 kDa, wherein the resulting red blood cells are not susceptible to hemolysis by any serum or plasma sample, such as by complement lysis. The RBC composition is particularly suitable for introduction into an individual in situations where the likelihood of an immune response is high, such as in alloimmune blood recipients or in trauma situations where the likelihood of transfusing an unmatched blood unit is high.

[0006] Advanced Drug Delivery Reviews 62:827-840 (2010) reviewed various attempts to encapsulate islets of Langerhans or produce a bioartificial pancreas to couple the islets with a recipient's immune system for analysis.

[0007] There remains a need for a treatment of blood products that can be used, for example, in emergency situations where a complete cross-matching process between donor and recipient is not possible. There is also a need for treatment of transplants to address antibody-mediated rejection associated with transplantation. Summary of the invention

[0008] The overall goal is to inhibit transfusion-associated antibody binding and agglutination.

[0009] Another overall goal is to inhibit antibody binding and antibody-mediated rejection associated with organ transplantation.

[0010] These and other objectives are met by the invention defined herein.

[0011] The present invention is defined in the independent technical solution. Other embodiments of the present invention are defined in the dependent technical solution.

[0012] One aspect of the invention relates to poly(ethylene glycol) phospholipid (PEG-phospholipid) molecules for selectively masking surface antigens of red blood cells and / or platelets in blood products from donors to inhibit the binding of antibodies to surface antigens when the blood products are transfused into uncross-matched or incompatible recipients. The PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da.

[0013] Another aspect of the invention relates to PEG-phospholipid molecules for selectively masking surface antigens of organ transplants from donors, including red blood cells, platelets and / or endothelial cells, to inhibit antibody binding to surface antigens and antibody-mediated rejection (AMR) associated with transplanting organ transplants into uncrossmatched or incompatible recipients.

[0014] Another aspect of the present invention relates to a blood product comprising red blood cells and / or platelets and PEG-phospholipid molecules anchored in the cell membrane of red blood cells and / or platelets and masking the surface antigens of red blood cells and / or platelets. The PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da.

[0015] Another aspect of the present invention relates to an in vitro method for treating red blood cells and / or platelets, the method comprising selectively masking surface antigens of red blood cells and / or platelets by adding in vitro PEG-phospholipid molecules to the red blood cells and / or platelets. The PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da.

[0016] Another aspect of the present invention relates to a method of transfusion, the method comprising adding PEG-phospholipid molecules to a blood product from a donor to selectively mask surface antigens on red blood cells and / or platelets present in the blood product. The PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da. The method also comprises transfusing the blood product into an uncrossmatched or incompatible recipient.

[0017] Another aspect of the present invention relates to a method for screening irregular antibodies. The method includes adding PEG-phospholipid molecules to a blood sample of a subject to selectively mask red blood cell surface antigens present in the blood sample. The PEG chain of the PEG-phospholipid molecule has an average molecular weight selected within the range of 3000 to 10000 Da. The method also includes screening for irregular antibodies that bind to red blood cells present in or obtained from the blood sample.

[0018] The PEG-phospholipid molecules of the embodiment can selectively mask surface antigens on red blood cells, platelets and / or endothelial cells. Therefore, blood products treated with PEG-phospholipid molecules can be transfused into uncross-matched or incompatible recipients, and reduce the risk of antibody binding and agglutination to surface antigens. Accordingly, organ transplants treated with PEG-phospholipid molecules can be transplanted into uncross-matched or incompatible recipients, and reduce the risk of antibody binding and AMR. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The embodiments, together with further objects and advantages thereof, may best be understood by reference to the following description taken in conjunction with the accompanying drawings, in which:

[0020] Figure 1 . Illustration of the hydrophobic interaction mechanism of PEG-phospholipid molecules with the lipid bilayer of cell membranes.

[0021] Figure 2 .Flow cytometric analysis of the binding of FITC-labeled PEG-phospholipids to CCRF-CEM cells.

[0022] Figure 3. In vitro results depicting the mechanism of action (MOA) of PEG-phospholipids. (A) When cells are coated with PEG-phospholipids, binding to surface antigens is inhibited. (B) When RBCs are coated with PEG-phospholipids, binding to blood group antigens is inhibited. (C) Inhibition of complement-mediated erythrocyte lysis.

[0023] Figure 4 . Binding to surface antigens using antibodies against large and small surface antigens (CD52 and CD4, respectively). Coating of cells with PEG-phospholipids resulted in almost complete inhibition of binding to the small surface antigen.

[0024] Figure 5. Agglutination test card for Rh phenotyping. (A) 0Rh+ blood sample treated with PEG-phospholipid molecules. (B) 0Rh+ control blood sample.

[0025] Figure 6. Agglutination test card for Rh phenotyping. (A) A Rh+ blood sample treated with PEG-phospholipid molecules. (B) A Rh+ control blood sample.

[0026] Figure 7. Agglutination test card for Rh phenotyping. (A) A Rh+ blood sample treated with PEG-phospholipid molecules. (B) A Rh+ control blood sample.

[0027] Figure 8 Binding of the LP recognition molecule CL-11 (n=5) on native and coated HUVEC after exposure to human plasma, as well as binding of Concanavalin A (a lectin with broad specificity) (n=3) not exposed to plasma, was analyzed by flow cytometry. CL-11 binding values ​​are presented after subtraction of CL-11 binding in the presence of 10 mM EDTA. The results indicate that the PEG-phospholipid coating is able to mask the receptor molecules for Concanavalin A and (to a lesser extent) CL-11. Statistical evaluation was performed by one-sample t-test and one-way ANOVA.

[0028] Fig. 9 Binding of the LP recognition molecule MBL on native and coated HUVECs after exposure to human plasma was analyzed by flow cytometry.

[0029] Fig.10 . The dissociation of PEG-phospholipids from cells was analyzed by incubating three million CCRF-CEM cells with 50 μL FAM-PEG-phospholipids (2 mg / mL) at room temperature for 30 minutes (n=3). After washing, the cells were cultured for 7 days and the amount of PEG-phospholipid binding was evaluated by flow cytometry (left) and confocal microscopy (right).

[0030] Fig.11.Two donor pigs underwent bilateral nephrectomy. The kidneys were then harvested and refrigerated for 24 hours. Biotinylated PEG-phospholipids were applied and incubated in both kidneys for 40 minutes. After 40 minutes, unbound biotin-PEG-phospholipids were flushed from the system and the kidneys were transplanted into recipient pigs, and initial biopsies were taken from the treated kidneys and native kidneys at the time of transplantation and 60 minutes later (n=4). The pigs were euthanized 12, 24, 48, and 72 hours later, and biopsies were taken from the transplanted and native kidneys. Fluorescence was detected by secondary FITC-streptavidin and confocal microscopy. The fluorescence of the native kidneys was compared with the transplanted kidneys. The half-life of PEG-phospholipids was calculated from the fluorescence images, and a single-phase exponential decay model was applied to fit the curve to the data points, and the t1 / 2 was calculated to be 14 hours (95% confidence interval 8-26).

[0031] Fig.12 In ANSM, fluorescence was detected in the urine of four PEG-phospholipid treated kidneys and native kidneys, confirming that PEG-phospholipids are excreted by the kidneys. Two-way repeated measures ANOVA (coated / uncoated); p=0.0013.

[0032] Fig.13 Wedge biopsies were taken at 1, 60, and 360 min and protein expression of nitrotyrosine, HO-1, and INOS was quantified by immunohistochemistry by confocal microscopy. No significant differences were found between treated and untreated tissues. Two-way repeated measures ANOVA (coated / uncoated); ns.

[0033] Fig.14 Complement (C3a, sC5b-9), coagulation (TAT), and contact system (FXIIa-C1INH) markers were sampled continuously from the renal veins of PEG-phospholipid treated kidneys and their controls for the first 60 minutes; systemically thereafter until 360 minutes. Two-way repeated measures ANOVA (coated / uncoated; TAT p=0.0042; C3a p=0.0002; sC5b-9 p=0.0042; FXIIa / C1INH p=0.0029).

[0034] Fig.15 Wedge biopsies were taken at 1, 60, and 360 minutes and analyzed immunohistochemically for C4d and C3b. Two-way repeated measures ANOVA (coated / uncoated); C4d ns; C3b p=0.013.

[0035] Fig.16Complement (C3a, sC5b-9) and coagulation (TAT) markers were used as indicators of thromboinflammation and were sampled serially from the renal vein of PEG-phospholipid treated kidneys and their controls at 60 minutes; then systemically at 24, 48, 72 and 96 hours. Two-way repeated measures ANOVA (coated / uncoated; TAT p=0.006; C3a p=0.0059; sC5b-9 p=0.0023) (n=6 treated groups + 4 control groups).

[0036] Fig.17 Wedge biopsies were taken at 5 minutes and 96 hours later and analyzed immunohistochemically for C3b and MAC. Two-way repeated measures ANOVA (coated / uncoated); C3bns; sC5b-9ns (n=6 treated groups + 4 controls).

[0037] Fig.18 .NET analysis was performed on biopsies of ANSM by electron microscopy imaging and showed strong NET deposition in the untreated control group. In untreated kidneys (upper row), dense reticular structures (NET deposition) were already observed in biopsies 1 minute after reperfusion and were mainly located in Bowman's space (BS), renal tubules and peritubular capillaries (PTC). In kidneys treated with PEG-phospholipids (lower figure), NET formation was significantly reduced and absent in larger areas of renal tissue. Resting neutrophils can be seen in kidneys treated with PEG-phospholipids (representative images of 6 analyzed).

[0038] Fig.19 PEG-phospholipid treated kidneys showed highly significant reductions in NET deposition at all locations (n=6). Two-way repeated measures ANOVA (coated / uncoated); glomeruli p≤0.0001; tubules p=0.0010; vessels p=0.0011.

[0039] Fig. 20 .Cytokine mRNA expression of pro-inflammatory cytokines in ANSM: RT-PCR was performed for pro-inflammatory cytokines and TF in wedge biopsies from individual kidneys and showed suppression throughout the observation period. Expressed as percentage of the respective value at reperfusion (5 min), two-way repeated measures ANOVA (coated / uncoated; IL-1β p=0.0021; IL-6 p<0.0001; TNF p=0.0077; TF p=0.0019) (n=6).

[0040] Fig.21Protein levels of proinflammatory cytokines in ANSM: Serial samples were drawn from the renal vein of PEG-phospholipid treated kidneys and controls for the first 60 min and then systemically until 360 min. Two-way repeated measures ANOVA (coated / uncoated; IL-1βns; IL-6 p=0.0005; TNF p=0.0328; TF p=0.0103) (n=6).

[0041] Fig. 22 Protein levels of cytokines in SM: Cytokines were sampled serially from the renal vein of PEG-phospholipid treated kidneys and their controls at 5 and 60 min; then systemically after 96 h. In most cases, IL-1α and IL-12 were already suppressed by PEG-phospholipid treatment at 5 min. At 60 min, all cytokines stabilized at a low steady state representing control values. After 96 h, all cytokines remained suppressed to baseline levels in treated animals, except IL-1RA and IL-8, which were unaffected. Two-way repeated measures ANOVA (coated / non-coated); IL-1α, IL-β, INFγ, IL-2, IL-4, IL-6, IL-10, IL-12, and IL-18 p<0.01; IL-1RA, TNF, and IL-8 ns (n=6 treated groups + 4 controls).

[0042] Fig.23 .Renal function was monitored by plasma creatinine levels before and after transplantation in SM (including CLSM and in vivo separation studies). Plasma creatinine levels were assessed at baseline before transplantation and then daily at 24, 48, 72, 96 hours. Two-way repeated measures ANOVA (coated / uncoated); p=0.0179 (n=6 treatment groups + 4 control groups).

[0043] Fig.24 . Corresponding data in CLSM. Two-way repeated measures ANOVA (coated / uncoated); p=0.0252 (n=5 treated groups+5 control groups).

[0044] Fig.25 .PEG-phospholipids inhibit the binding of anti-HLA class I antibody W6 / 32 to PBMCs.

[0045] Fig.26 .PEG-phospholipids inhibit the binding of anti-HLA-ABC G46-2.6 to PBMCs. DETAILED DESCRIPTION

[0046] The present invention generally relates to poly(ethylene glycol) phospholipid (PEG-phospholipid) molecules and their use in selectively masking cell surface antigens.

[0047] Traditionally, crossmatching is performed on blood products used in transfusions and on organs transplanted from donors to recipients. This crossmatching is used to prevent transfusion-related agglutination or antibody-mediated rejection (AMR) of transplanted organs. Both of these processes are mediated by the recipient's antibodies against surface antigens present on donor blood or organ cells. However, in emergency situations, there may not be enough time to perform a complete crossmatching process to save the recipient's life. Therefore, it is necessary to treat blood products and / or organs, which can be used to inhibit harmful reactions, such as agglutination or AMR, which would otherwise occur when non-crossmatched blood is transfused or non-crossmatched organs are transplanted.

[0048] The present invention relates to the use of poly(ethylene glycol) phospholipid (PEG-phospholipid) molecules to produce a transient, non-toxic artificial layer on the cell surface of a blood product or organ. This shielding PEG layer effectively masks the surface antigens on the cell surface from the influence of the receptor's antibodies against the surface antigens. Therefore, PEG-phospholipid treatment of blood products or organs before infusion or transplantation can reduce the risk of antibody binding to the surface antigen, thereby reducing the risk of agglutination or AMR by masking the surface antigens of the antibodies in the recipient body.

[0049] PEG-phospholipid molecules, by virtue of their phospholipid domains, can be uniformly anchored to the lipid membrane of cells through hydrophobic interactions, thereby generating non-static artificial layers, see Figure 1 The PEG domain of the PEG-phospholipid molecule is negatively charged and is able to protect the surface from close interactions with macromolecules, including antibodies. In addition, cell surface polymer coatings (CSPCs) with PEG-phospholipid molecules prevent nonspecific adsorption of macromolecules such as albumin. This is an important finding because intracellular adsorption of proteins is known to induce biological responses such as activation of coagulation and complement systems.

[0050] The experimental data provided herein show that the PEG-phospholipid molecules of the embodiments are able to mask blood group antigens (e.g., A and B antigens) and rhesus factors (e.g., RhD, RhC, Rhc, RhE, and Rhe) present on endothelial cells (i.e., red blood cells). Due to this surface antigen masking, agglutination and cell lysis are inhibited by masking the surface antigens of the antibodies, thereby preventing or at least significantly inhibiting the binding of antibodies to surface antigens on red blood cells.

[0051] In addition, the experimental data presented herein show that the masking effect depends on the length of the PEG polymer and the size of the surface antigen on the cell surface, and the surface antigen masking achieved by the PEG-phospholipid molecules of the embodiment is selective. For example, a PEG-phospholipid molecule with a PEG domain or chain having a molecular weight of about 5kDa has a length of about 6nm, and a PEG layer of 6nm is produced when anchored in the cell membrane. Therefore, this PEG-phospholipid molecule can selectively mask surface antigens that are no more than about 6nm or slightly higher than 6nm from the cell surface. For example, this PEG-phospholipid molecule can effectively mask type B antigens and differentiation clusters (CD52) (also referred to as CAMPATH-1 antigens), both of which are about 1nm from the cell surface. In addition, CD8 obtains partial masking, while CD4 does not see obvious masking. The latter extends about 15nm from the cell surface, while the stem region of CD8 makes the molecule protrude less from the cell membrane, even if the size of CD8 and CD4 is similar.

[0052] One aspect of the invention relates to PEG-phospholipid molecules for selectively masking surface antigens of red blood cells and / or platelets in blood products from donors to inhibit binding of antibodies to surface antigens associated with transfusion of blood products into uncrossmatched or incompatible recipients. The PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da.

[0053] A related aspect of the invention defines the use of a PEG-phospholipid molecule in the manufacture of a medicament for inhibiting antibody binding to a surface antigen associated with transfusing a blood product comprising red blood cells and / or platelets having surface antigens selectively masked by the PEG-phospholipid molecule into an uncrossmatched or incompatible recipient. The PEG chain of the PEG-phospholipid molecule has an average molecular weight selected within the range of 3000 to 10000 Da.

[0054] The PEG-phospholipid molecules of the embodiments selectively mask surface antigens of red blood cells and / or platelets, thereby inhibiting agglutination by inhibiting the binding of antibodies to the surface antigens associated with transfusion of blood products into uncrossmatched or incompatible recipients. Thus, one aspect of the invention relates to PEG-phospholipid molecules for selectively masking surface antigens of red blood cells and / or platelets in a blood product from a donor to inhibit agglutination associated with transfusion of the blood product into an uncrossmatched or incompatible recipient.

[0055] Very surprisingly, according to the disclosure of WO 2004 / 050897, PEG-phospholipid molecules having a PEG chain or domain with an average molecular weight selected from the range of 3 to 10 kDa can be used to selectively mask surface antigens of red blood cells and / or platelets. The document reacts activated PEG compounds with a molecular weight of 20-40 kDa to covalently attach the PEG compounds to the surface of red blood cells. The experimental data provided in the document show that the molecular weight of methoxy-PEG (mPEG) needs to be at least 20 kDa to effectively mask antigens on red blood cells, thereby inhibiting the binding of antibodies to these cells. When smaller mPEG molecules (5 kDa and 10 kDa) were tested, it was concluded that they caused red blood cell lysis at the level required for masking antigens.

[0056] Compared with WO 2004 / 050897 (20-40 kDa), the PEG-phospholipid molecules of the present invention have smaller PEG chains (3-10 kDa) and do not cause any cell lysis at a level that can effectively mask red blood cell surface antigens. Therefore, compared with chemically reacting mPEG molecules with proteins and other macromolecules anchored in the red blood cell cell membrane, using PEG-phospholipid molecules with phospholipid domains to anchor PEG-phospholipid molecules in the cell membrane has significant advantages.

[0057] Blood products are typically whole blood products, but may also be processed and / or processed blood products that contain erythrocytes (erythrocyte / red blood cell), platelets (thrombocyte / platelet), or erythrocytes and platelets. An example of a processed blood product is an enriched blood product containing enriched erythrocytes, enriched platelets, or enriched erythrocytes and platelets. For example, a red blood cell sample obtained after centrifugation of whole blood is an enriched erythrocyte blood product, a buffy coat obtained after centrifugation of whole blood is an enriched platelet blood product, and removal of plasma after centrifugation of whole blood leaves a combined enriched erythrocyte and platelet blood product.

[0058] Another aspect of the invention relates to PEG-phospholipid molecules for selectively masking surface antigens of organ transplants from donors, including red blood cells, platelets and endothelial cells, to inhibit antibody binding to surface antigens and antibody-mediated rejection (AMR) associated with transplanting organ transplants into uncrossmatched or incompatible recipients.

[0059] A related aspect of the invention defines the use of PEG-phospholipid molecules in the manufacture of a medicament for inhibiting antibody binding to surface antigens and / or antibody-mediated rejection (AMR) associated with transplanting an organ graft comprising red blood cells, platelets and / or endothelial cells having surface antigens selectively masked by the PEG-phospholipid molecules into an uncrossmatched or incompatible recipient.

[0060] The PEG-phospholipid molecules of the embodiments selectively mask surface antigens of erythrocytes, platelets and / or endothelial cells, thereby inhibiting agglutination and AMR by inhibiting the binding of antibodies to surface antigens associated with transplanting an organ transplant into an uncrossmatched or incompatible recipient. Thus, this aspect of the invention relates to PEG-phospholipid molecules for selectively masking surface antigens of an organ transplant from a donor, the organ transplant comprising erythrocytes, platelets and endothelial cells, to inhibit agglutination and antibody-mediated rejection (AMR) associated with transplanting a cell or organ transplant into an uncrossmatched or incompatible recipient.

[0061] Antibody-mediated rejection (AMR), also known as B-cell-mediated or humoral rejection, is a serious complication following organ transplantation, such as kidney transplantation. Although less than 10% of kidney transplant recipients develop AMR, up to 30% of these patients experience graft loss as a result. AMR is mediated by antibodies against the allograft (particularly anti-HLA antibodies and A / B blood group antibodies) and results in histological changes in the allograft vasculature that are distinct from cellular rejection (T-cell-mediated rejection). Therefore, AMR is a separate disease process from cellular rejection. AMR is initially characterized by microvascular inflammation, endothelial damage, and serological evidence of donor-specific antibodies (DSA). AMR symptoms may progress to transplant glomerulopathy, a form of advanced glomerular damage and remodeling.

[0062] Standard treatment for AMR includes plasma exchange and intravenous immunoglobulin to remove and neutralize antibodies, respectively. Drugs targeting B cells (rituximab and alemtuzumab), plasma cells (bortezomib), and the complement system (eculizumab) have also been used to treat AMR in kidney transplant recipients.

[0063] Therefore, AMR is a rejection process that is different from the initial cellular rejection reaction driven by the innate immune system and occurs immediately after the organ transplantation. Therefore, AMR follows the initial cellular rejection process. The half-life of the PEG-phospholipids of the present invention in pigs is about 14 hours, that is, long before the onset of the AMR process. However, as shown in the experimental part, the PEG-phospholipid molecules of the present invention are still able to suppress cytokines even 4 days after transplantation. For example, Fig. 22 As shown, 60 minutes after transplantation, there were no significant differences between untreated control kidneys and PEG-phospholipid-treated kidneys in several cytokines, including IL-1α, IL-1β, IFNγ, IL-2, IL-4, IL-6, IL-01, IL-12, and IL-18. However, at 4 days after kidney transplantation, the levels of these cytokines were significantly lower in recipients who received PEG-phospholipid-treated kidneys compared to recipients who received untreated control kidneys. This was very surprising because PEG-phospholipid molecules, which have a half-life of only 14 hours, disappeared from the treated kidneys 4 days after transplantation, but their effects were still present.

[0064] The long-term effects seen with PEG-phospholipid treatment of organ transplants imply that PEG-phospholipids may protect against the adaptive immune system and AMR. The sustained and significant suppression of IL-6 supports this notion, as inhibition of IL-6 / IL-6R signaling is considered a new therapeutic option for the prevention and treatment of allograft injury and AMR. Clinical trial evidence supports the use of IL-6 blockade for desensitization and treatment of AMR in renal transplantation (Curr Transplant Reports 8:1–14(2021), J Am Soc Nephrol 20:1032–1040(2009), Transplantation 101:32–44(2017)). Fig. 22 as well as Figure 20-21 As shown in Figure 3, PEG-phospholipid molecules led to significant inhibition of IL-6, which is very important for targeting and treating AMR.

[0065] As used herein, an uncrossmatched recipient refers to a recipient for which a crossmatch has not been performed between the donor and recipient of a blood product or an organ transplant. As used herein, an incompatible recipient refers to a recipient that is incompatible with at least one surface antigen on red blood cells and / or platelets in a blood product, i.e., a recipient that has antibodies against at least one surface antigen on red blood cells and / or platelets in an organ transplant, or at least one surface antigen on red blood cells, platelets, and / or endothelial cells.

[0066] The present invention is not limited to allogeneic organ transplantation, i.e. organ xenotransplantation. In sharp contrast, the present invention also provides advantages associated with xenogeneic organ transplantation, i.e. xenotransplantation. For example, an organ transplant from a donor of one mammalian species (usually a non-human mammalian species) can be treated with the PEG-phospholipid molecules of the present invention to selectively mask the surface antigens of the organ transplant before transplantation into a recipient of another mammalian species (usually a human).

[0067] In one embodiment, the receptors are uncrossmatched receptors. In another embodiment, the receptors are incompatible receptors.

[0068] As used herein, an organ transplant includes a whole organ or a portion of a tissue or an organ to be transplanted into a recipient. Illustrative (but non-limiting) examples of organ transplants include kidneys, livers, pancreas, hearts, lungs, uteruses, bladders, thymus, and intestines (including portions thereof).

[0069] Agglutination as used herein refers to the aggregation of cells that occurs when an antigen is mixed with its corresponding antibody. For example, when a blood transfusion is given to an uncross-matched or incompatible recipient, antibodies in the recipient may react with surface antigens on red blood cells and / or platelets, resulting in the red blood cells and / or platelets aggregating and sticking together, causing them to agglutinate.

[0070] The selective masking of the surface antigens on the red blood cells by the PEG-phospholipid molecules of the embodiment includes the selective masking of the blood group antigens. Such blood group antigens are preferably selected from the group consisting of A antigens and B antigens. For example, a blood product comprising red blood cells from a type A blood donor is processed to selectively mask the A antigens on the red blood cells to produce a blood product that can be provided not only to type A recipients, but also to type B, type AB or type 0 recipients, and the risk of any initial agglutination reaction associated with blood transfusion will not occur or at least significantly reduce. Therefore, in one embodiment, the surface antigen is a blood group antigen. In a specific embodiment, the surface antigen is selected from the group consisting of A antigens and B antigens.

[0071] In another embodiment, the surface antigen is Rhesus Factor.In a specific embodiment, the surface antigen is selected from the group consisting of RhD, RhC, Rhc, RhE and Rhe.

[0072] Thus, in one embodiment, the PEG-phospholipid molecule selectively masks blood group antigens, such as A antigen and / or B antigen. In another embodiment, the PEG-phospholipid molecule selectively masks rhesus factors, such as RhD, RhC, Rhc, RhE and / or Rhe. In a further embodiment, the PEG-phospholipid molecule selectively masks blood group antigens, such as A antigen and / or B antigen, and selectively masks rhesus factors, such as RhD, RhC, Rhc, RhE and / or Rhe.

[0073] In a preferred embodiment, the PEG-phospholipid molecules of the embodiments selectively mask any blood group antigens and any Rhesus factor present on the cell surface of red blood cells in the blood product.

[0074] Accordingly, the endothelial cells of organ transplantation contain surface antigens in the form of blood group antigens. Therefore, the PEG-phospholipid molecules of the embodiment can selectively mask any blood group antigens present on the cell surface of endothelial cells in organ transplantation. In addition, endothelial cells contain surface antigens in the form of human leukocyte antigens (HLA). In an embodiment, the PEG-phospholipid molecules of the embodiment can therefore selectively mask any HLA present on the cell surface of endothelial cells in organ transplantation. In a specific embodiment, HLA is selected from the group consisting of HLA A, HLA B and HLA C, which are the major antigens of the major histocompatibility complex (MHC) class I. This MHC class I also includes minor HLA antigens in the form of HLA E, HLA F and HLA G. MHC class I proteins form functional receptors on most nucleated cells of the body, while MHC class II proteins, such as HLA-DP, HLA-DG, HLA-DR, HLA-DM and HLA-DO, only appear on antigen presenting cells, B cells and T cells.

[0075] In addition, the PEG-phospholipid molecules of this embodiment can selectively mask CL-11. During transplantation, CL-11 expression in organ transplants (e.g., kidney transplants) can recognize ischemic cells and promote complement activation through the lectin (LP) pathway. In addition, other recognition molecules of LP (e.g., MBL) are also associated with complement activation in organ transplants. Therefore, selectively masking cell membrane proteins on endothelial cells with a PEG-phospholipid coating, shielding the endothelial membrane of organ transplants, will reduce complement activation associated with organ transplants.

[0076] Platelets contain a surface antigen called human platelet antigen (HPA). In one embodiment, the surface antigen is HPA. In a specific embodiment, the surface antigen is selected from the group consisting of HPA-1, HPA-2, HPA-3, HPA-4, HPA-5, HPA6, HPA-9 and HPA-15. In another specific embodiment, the surface antigen is selected from the group consisting of HPA-1, HPA-2, HPA-3, HPA-4, HPA-5, HPA6 and HPA-15. In a further specific embodiment, the surface antigen is HPA-1.

[0077] Processing of blood products containing both erythrocytes and platelets or cell or organ transplants containing platelets in addition to erythrocytes and / or endothelial cells results in the selective masking of blood group antigens, rhesus factor and HPA by PEG-phospholipid molecules.

[0078] In one embodiment, when anchored in the cell membrane, the PEG-phospholipid molecule has an average extracellular length selected in the interval of 4nm to 8nm. In a specific embodiment, when anchored in the cell membrane, the PEG-phospholipid molecule has an average extracellular length selected in the interval of 5nm to 7nm, and preferably about 6nm.

[0079] The average extracellular length used herein means that the length of a single PEG-phospholipid molecule extending from the cell surface when anchored to the cell membrane may be longer or shorter than the average extracellular length. However, the average extracellular length is the average or mean of the individual lengths of the PEG-phospholipid molecules.

[0080] The above average extracellular length is sufficient to mask blood group antigens, rhesus factor, HLA and HPA, but is not sufficient to effectively mask extracellular or transmembrane molecules and proteins in the cell membrane, which have extracellular domains or portions that are significantly longer or greater than this average extracellular length of PEG-phospholipid molecules.

[0081] In one embodiment, the PEG-phospholipid molecule has formula (I):

[0082]

[0083] In one embodiment, n, m are independently selected from integers in the range of 10 to 16. The parameters n, m are preferably independently 10, 12, 14 or 16, and more preferably, n=m=14.

[0084] In one embodiment, p is selected so that the PEG chain or domain has an average molecular weight selected in the range of 1000Da to 40000Da. Preferably, the parameter p is selected so that the average molecular weight of the PEG chain is 3000 to 10000Da, more preferably about 5000Da, such as 4500Da to 5500Da, 4600Da to 5400Da, 4700Da to 5300Da, 4800Da to 5200Da or 4900Da to 5100Da.

[0085] The average molecular weight defined herein means that individual PEG-phospholipid molecules may have molecular weights different from this average molecular weight, but the average molecular weight represents the average molecular weight of the PEG-phospholipid molecules. This further means that there will be a natural distribution of molecular weights around this average molecular weight of a sample of PEG-phospholipid molecules.

[0086] In one embodiment, the terminal group R is selected from the group consisting of H, methyl (CH3) and C1-C4 alkylamine. In one embodiment, the C1-C4 alkylamine is n-propylamine. In a preferred embodiment, the terminal group R is methyl.

[0087] In one embodiment, the PEG-phospholipid molecule is N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.

[0088] In another embodiment, the end group R may include a maleimide group, a biotin group, a streptavidin group, an avidin group or a functionalized molecule. In the case of a functionalized molecule, it is preferably selected from the group consisting of a complement inhibitor, a coagulation inhibitor, a platelet inhibitor, a molecule capable of binding a complement inhibitor, a molecule capable of binding a coagulation inhibitor, a molecule capable of binding a platelet inhibitor and a mixture thereof.

[0089] In this case, the maleimide group, biotin group, streptavidin group, avidin group or functionalized molecule is preferably connected to the PEG-phospholipid molecule of formula (I) via a linker. An illustrative (but non-limiting) example of such a linker is -CH2CH2CH2NHC(O)CH2CH2-. For example, the terminal group R comprising such a linker and a maleimide group is presented in formula (II):

[0090]

[0091]

[0092] The functionalized molecule can be attached to the PEG-phospholipid molecule of formula (I) via a linker. Thus, in this embodiment, the terminal group R has the general formula L-(FM), wherein L represents a linker and (FM) represents a functionalized molecule.

[0093] Illustrative but non-limiting examples of complement inhibitors include factor H; C4b binding protein (C4BP); the N-terminal 4 to 6 short consensus repeats (SCR) of complement receptor 1 (CR1), also known as the C3b / C4b receptor or cluster of differentiation 35 (CD35); CD46 complement regulatory protein (CD46), also known as membrane cofactor protein (MCP); and complement decay accelerating factor (DAF), also known as CD55.

[0094] Illustrative but non-limiting examples of coagulation inhibitors include heparin.

[0095] Illustrative but non-limiting examples of platelet inhibitors are adenosine diphosphate (ADP) degrading enzymes such as apyrase and ectonucleoside triphosphate diphosphohydrolase-1 (NTPDase1), also known as CD39.

[0096] Illustrative but non-limiting examples of molecules capable of binding complement inhibitors are factor H binding peptides, such as 5C6 (Nilsson et al., Autoregulation of thromboinflamm ation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials. 2013, 34(4):985-994), and C4BP binding peptides, such as streptococcal M protein-derived peptides M2-N, M4-N or M22-N (Engberg et al., Inhibition of complement activation on a model biomaterial surface by strepto coccal M protein-derived peptides. Biomaterials. 2009, 30(13):2653-2659).

[0097] An illustrative but non-limiting example of a molecule capable of binding a coagulation inhibitor is a heparin-binding peptide (Asif et al., Heparinization of cell surfaces with short peptide-conjugated PEG-phospholipid regulates thromboinflammation in transplation of human MSCs and hepatocytes. Acta Biomateriala. 2016, 35: 194-205).

[0098] Thus, in one embodiment, the functionalized molecule is selected from the group consisting of a heparin binding peptide, the N-terminal 4 to 6 SCRs of CR1, CD46, DAF, a Factor FI binding molecule, an ADP degrading enzyme, and mixtures thereof.

[0099] The fatty acid chains of the PEG-phospholipid molecule may be saturated. At least one or two fatty acid chains may be unsaturated, i.e., contain at least one -CH=CH- group, at least one -C≡C- group, or a combination thereof. Each fatty acid chain may be straight or branched.

[0100] In one embodiment, the PEG-phospholipid molecules have an average molecular weight selected in the interval of 5 to 7 kDa as determined by gel permeation chromatography. In a specific embodiment, the PEG-phospholipid molecules have an average molecular weight selected in the interval of 5.5 to 6.6 kDa as determined by gel permeation chromatography. In a preferred embodiment, the PEG-phospholipid molecules have an average molecular weight selected in the interval of 5.8 to 6.0 kDa as determined by gel permeation chromatography, for example, about 5.9 kDa.

[0101] In one embodiment, the lipid portion or domain of the PEG-phospholipid molecule is a phospholipid portion or domain.

[0102] In one embodiment, the lipid portion or domain of the PEG-phospholipid molecule is 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (DPPE). Other non-limiting examples of lipid portions or domains of PEG-phospholipid molecules include 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), also known as 1,2-ditetradecanoyl-sn-glycero-3-phosphoethanolamine and [(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE).

[0103] In one embodiment, the PEG portion or domain of the PEG-phospholipid molecule has an average degree of polymerization (DP) selected in the interval of 105 to 125. In a specific embodiment, the PEG portion or domain of the PEG-phospholipid molecule has an average DP selected in the interval of 110 to 120. In a preferred embodiment, the PEG portion or domain of the PEG-phospholipid molecule has an average DP selected in the interval of 114 to 116, for example about 115.

[0104] In one embodiment, the PEG-phospholipid molecule comprises at least one sulfated glycosaminoglycan. In a specific embodiment, the PEG-phospholipid molecule comprises a K linker that interconnects at least one sulfated glycosaminoglycan and the PEG-phospholipid. n C and / or CKn In this particular embodiment, C is cysteine, K is lysine, and n is zero or a positive integer equal to or less than 20, preferably, n is selected in the interval of 0 to 15, and more preferably, n is selected in the interval of 0 to 10.

[0105] In one embodiment, the sulfated glycosaminoglycan is fragmented heparin. In a specific embodiment, the average molecular weight of the fragmented heparin is selected from the interval of 2.5 kDa to 15 kDa, preferably from the interval of 5 kDa to 10 kDa, and more preferably from the interval of 7 kDa to 9 kDa.

[0106] In one embodiment, any free amino groups in the sulfated glycosaminoglycan-PEG-phospholipid are converted to carboxyl groups.

[0107] Such PEG-phospholipid molecules can be produced by mixing a cationic-PEG-phospholipid comprising at least one amino group with a sulfated glycosaminoglycan comprising at least one carbonyl group, preferably at least one aldehyde group, to form a Schiff base intermediate. A reducing agent is added to the Schiff base intermediate to form the sulfated glycosaminoglycan-PEG-phospholipid.

[0108] For example, α-N-hydroxysuccinimidyl-ω-maleimidyl polyethylene glycol (NHS-PEG-Mal), triethylamine, and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (DPPE) are mixed in dichloromethane. The next step involves precipitating the resulting maleimide-bound PEG-phospholipid by adding ether to the mixture of NHS-PEG-Mal and DPPE in dichloromethane.

[0109] Preferred sulfated glycosaminoglycans, i.e. fragmented heparin, preferably contain at least one carbonyl group, more preferably at least one aldehyde group. Such fragmented heparin can be obtained by mixing an acidic solution with an aqueous solution of sodium nitrite (NaNO2) to form a mixed solution. The pH of the mixed solution is adjusted to a range of 2 to 6, preferably 3 to 5 and more preferably 4. Heparin, preferably sodium heparin, is added to the mixed solution to form a heparin solution, and the pH of the heparin solution is adjusted to a range of 6 to 8, preferably 6.5 to 7.5 and more preferably 7, to form a fragmented heparin containing at least one carbonyl group. Optionally, the fragmented heparin containing at least one carbonyl group is dialyzed with water, and the fragmented heparin containing at least one carbonyl group is freeze-dried.

[0110] An illustrative example of a reducing agent added to the Schiff base is sodium cyanoborohydride.

[0111] In one embodiment, when anchored in the cell membrane of red blood cells and / or platelets or organ transplants, the PEG-phospholipid molecule is a separate or single PEG-phospholipid molecule. This means that the PEG-phospholipid molecules are not interconnected or connected by any connecting molecules or joints (e.g., polyvinyl alcohol (PVA) or multi-arm PEG-SH), with the purpose of interconnecting the individual PEG-phospholipid molecules and forming a layered surface masking or camouflage on the cell surface.

[0112] Another aspect of the present invention relates to a blood product comprising red blood cells and / or platelets and PEG-phospholipid molecules anchored in the cell membrane of red blood cells and / or platelets and masking the surface antigens of red blood cells and / or platelets. The PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da.

[0113] Another aspect of the present invention relates to an in vitro method for treating red blood cells and / or platelets. The method comprises selectively masking surface antigens of red blood cells and / or platelets by adding in vitro PEG-phospholipid molecules to red blood cells and / or platelets. The PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da.

[0114] In blood transfusion services, recipients are traditionally screened for irregular antibodies so that suitable compatible blood can be selected. These irregular antibodies are pre-existing antibodies that may have been produced by the recipient after a previous transfusion and / or after a previous delivery. In general, irregular antibodies are all non-ABO antibodies, although the term is mainly used for non-ABO alloantibodies that may cause transfusion incompatibility. Irregular antibodies are most commonly IgG-type, and they first appear after contact with foreign antigens. Exemplary but non-limiting examples of such irregular antibodies include anti-c, anti-Cw, anti-D, anti-E, anti-Fya, anti-Jka, anti-Kell, anti-Kpb, anti-Lea, anti-Leb (Lewis), anti-Lua, anti-Lub, anti-M, anti-N, anti-P1, anti-Public, anti-S, anti-s and auto-Pap antibodies. Since patients may have more than one of these irregular antibodies, the identification of antibodies may be difficult. To simplify identification, selectively masking the surface antigens will make identification easier because at least a portion of the surface antigens present on the surface of red blood cells can be masked and hidden by the PEG-phospholipid molecules of the embodiments.

[0115] Therefore, one aspect of the present invention relates to a method for screening irregular antibodies. The method includes adding PEG-phospholipid molecules to a blood sample of a subject to selectively mask red blood cell surface antigens present in the blood sample. The method also includes screening for irregular antibodies that bind to red blood cells present in or obtained from the blood sample. The PEG chain of the PEG-phospholipid molecule has an average molecular weight selected within the range of 3000 to 10000 Da.

[0116] The initial step of the method selectively masks the A and / or B antigens present on the surface of red blood cells, but does not selectively mask all surface antigens, irregular antibodies can be produced and bound to the surface antigens. Then the treated blood sample can be subjected to an irregular antibody screening test. The screening of antibodies is usually performed by performing a Coombs test, also known as an antiglobulin test or red blood cell antibody screening. There are two types of Coombs tests: direct and indirect. The direct Coombs test includes collecting red blood cells from a blood sample of a subject and preferably washing the red blood cells. The collected and optionally washed red blood cells are then incubated with an anti-human antibody (Coombs reagent), which binds to the Fc region of any irregular antibodies present in the blood sample and bound to surface antigens on red blood cells. If there are any irregular antibodies in the blood sample, the anti-human antibodies bind to the human irregular antibodies on the red blood cells, causing red blood cell agglutination and forming connections between the red blood cells. In a direct Coombs test, the PEG-phospholipid molecule of the embodiment is added to the blood sample before collecting the red blood cells, and / or is preferably added to the red blood cells collected from the blood sample.

[0117] The indirect Coombs test involves mixing a donor's blood sample with a recipient's serum sample. Any irregular antibodies present in the recipient's serum sample may bind to surface agents present on red blood cells in the donor's blood sample, thereby forming an antibody-antigen complex. If the recipient's serum sample contains any irregular antibodies that can bind to surface antigens on red blood cells in the donor's blood sample, an anti-human antibody (Coombs reagent) is added to the mixture to cause red blood cell agglutination, just like in a direct Coombs test. In a direct Coombs test, the PEG-phospholipid molecule of the embodiment can be added to the donor's blood sample, preferably before mixing with the recipient's serum sample.

[0118] The irregular antibody screening method is an in vitro screening method.

[0119] Another aspect of the present invention relates to a method of transfusion. The method comprises adding PEG-phospholipid molecules to a blood product from a donor to selectively mask surface antigens on red blood cells and / or platelets present in the blood product. The method also comprises transfusing the blood product into an uncross-matched or incompatible recipient. The PEG chain of the PEG-phospholipid molecule has an average molecular weight selected within the range of 3000 to 10000 Da.

[0120] The PEG-phospholipid molecules of the embodiments can be added to blood products or in vitro cells at selected concentrations to effectively selectively mask surface antigens on red blood cells and / or platelets, for example in blood products. Thus, in one embodiment, the final concentration of the PEG-phospholipid molecules in the blood product can depend on the amount of red blood cells and / or platelets in the blood product.

[0121] In typical embodiments, PEG-phospholipid molecules can be added to cells, blood products or cell transplants to reach a final concentration of PEG-phospholipid molecules in cells, blood products or cell transplants, the final concentration being selected in the interval of 0.25mg / ml to 25mg / ml, preferably 0.25mg / ml to 10mg / ml. In specific embodiments, the final concentration of PEG-phospholipid molecules in cells, blood products or cell transplants is 0.25mg / ml to 5mg / ml, preferably 0.5mg / ml to 4mg / ml or 1mg / ml to 3mg / ml. In preferred embodiments, the final concentration of PEG-phospholipid molecules in cells, blood products or cell transplants is 1.5mg / ml to 2.5mg / ml, for example about 2mg / ml.

[0122] The PEG-phospholipid molecules can be added in the form of a solution of the PEG-phospholipid molecules in a solvent, preferably an aqueous solvent. Non-limiting but illustrative examples of such aqueous solvents include saline, buffered solutions, and organ preservation solutions.

[0123] The surface antigen and PEG-phospholipid embodiments described above also apply to these aspects of the embodiments.

[0124] In transplantation, especially in living donor kidney transplantation, ABO blood group incompatibility is an obstacle to effective transplantation. In order to transplant under these conditions, it is traditionally necessary to remove anti-ABO antibodies over several weeks using plasmapheresis and anti-CD20 antibodies. This pretreatment over several weeks is very time-consuming and cumbersome. Therefore, it is necessary to treat the transplant and the graft, for example, to mask the ABO antigens, so as to facilitate transplantation.

[0125] An organ transplant can be treated with the PEG-phospholipid molecules of the embodiments by administering the PEG-phospholipid molecules to the vasculature of the organ transplant and / or immersing the organ transplant in a solution comprising the PEG-phospholipid molecules, preferably an organ preservation solution.

[0126] For example, a solution comprising PEG-phospholipid molecules is infused ex vivo into the vasculature of an organ transplant and optionally into the parenchyma of the organ transplant. The solution comprising PEG-phospholipid molecules is preferably incubated ex vivo in the vasculature and optionally in the parenchyma to be able to coat at least a portion of the endothelial lining of the vasculature and preferably the parenchyma with PEG-phospholipid molecules.

[0127] In one embodiment, the ex vivo incubation step comprises incubating a solution comprising PEG-phospholipid molecules ex vivo in the vasculature and optionally the parenchyma to be able to coat at least a portion of the endothelial lining of the vasculature, and preferably the parenchyma, with the PEG-phospholipid molecules while maintaining the organ graft immersed in an organ preservation solution, preferably an organ preservation solution comprising PEG-phospholipid molecules.

[0128] Thus, ex vivo processing of an organ graft involves introducing PEG-phospholipid molecules into the vasculature of the organ graft and allowing the PEG-phospholipid molecules to interact and bind to endothelial and parenchymal cell membranes therein.

[0129] The interaction between the PEG-phospholipid molecules and the lipid bilayer membranes of the endothelial cells and optionally the parenchyma (e.g. renal parenchyma in the case of the kidney) is preferably performed ex vivo while the organ transplant is immersed or immersed in an organ preservation solution, preferably an organ preservation solution comprising PEG-phospholipid molecules.

[0130] In a specific embodiment, the organ transplant is first infused ex vivo into the vascular system of the organ transplant, and optionally into the parenchyma of the organ transplant, with a solution containing PEG-phospholipid molecules. This ex vivo infusion is advantageously performed as soon as possible after the organ is explanted and removed from the donor. The perfused organ is then immersed in an organ preservation solution, which preferably contains PEG-phospholipid molecules, and preserved therein, preferably at a reduced temperature of, for example, about 4°C.

[0131] In another specific embodiment, the organ is first immersed in an organ preservation solution, preferably comprising PEG-phospholipid molecules, and then the solution comprising PEG-phospholipid molecules is infused ex vivo into the vascular system of the organ, and optionally into the parenchyma of the organ. This ex vivo infusion can be performed while the organ is immersed in the organ preservation solution, which preferably comprises PEG-phospholipid molecules. Alternatively, the organ is temporarily removed from the organ preservation solution for ex vivo infusion, and then placed back into the organ preservation solution, which preferably comprises PEG-phospholipid molecules.

[0132] In one embodiment, the method further comprises infusing the organ preservation solution into the vascular system ex vivo to flush out unbound PEG-phospholipid molecules from the vascular system. Therefore, it is preferred to use the organ preservation solution to wash out unbound PEG-phospholipid molecules in one or more (i.e., at least two) washing steps.

[0133] In one embodiment, the ex vivo infusion of a solution comprising PEG-phospholipid molecules comprises clamping one of an artery and a vein of a vascular system ex vivo. This embodiment also includes infusing a solution comprising PEG-phospholipid molecules ex vivo into the other of the artery and the vein, and clamping the other of the artery and the vein ex vivo.

[0134] In another embodiment, the solution containing the PEG-phospholipid molecules is infused into the artery (or vein) of the vascular system of the organ transplant until the solution appears in the vein (or artery) of the organ transplant. This confirms that the solution containing the PEG-phospholipid molecules has filled the vascular system. At this point, the artery and vein are clamped.

[0135] The solution comprising PEG-phospholipid molecules can be added via a vein or an artery. In a specific embodiment, the solution is infused into an artery. In this specific embodiment, an optional initial clamping of the vein of the vascular system is then preferably performed.

[0136] The solution containing the PEG-phospholipid molecules is preferably incubated in the vascular system ex vivo for a period of 10 minutes to 48 hours to allow the PEG-phospholipid molecules to interact hydrophobically with the endothelial cell membranes, thereby coating at least a portion of the vascular system of the organ transplant. The ex vivo incubation is preferably performed for 20 minutes to 36 hours, and more preferably 30 minutes to 24 hours, such as 30 minutes to 12 hours, to 8 hours, to 4 hours or to 1 hour.

[0137] The amount of the solution comprising PEG-phospholipid molecules infused into the vascular system depends on the type of organ and the size of the organ (adult and child). In general, the volume of solution should be enough to fill the vascular system of the organ. In most practical applications, 5ml to 500ml of the solution comprising PEG-phospholipid molecules is infused in vitro into the vascular system. In a preferred embodiment, 5ml to 300mL and preferably 10mL to 250mL of the solution comprising PEG-phospholipid molecules is infused in vitro into the vascular system.

[0138] In one embodiment, the solution comprises 0.25 mg / ml to 25 mg / ml, preferably 0.25 mg / ml to 10 mg / ml of PEG-phospholipid molecules. In a specific embodiment, the solution comprises 0.25 mg / ml to 5 mg / ml, preferably 0.5 mg / ml to 4 mg / ml or 1 mg / ml to 3 mg / ml of PEG-phospholipid molecules. In a preferred embodiment, the solution comprises 1.5 mg / ml to 2.5 mg / ml, for example about 2 mg / ml of PEG-phospholipid molecules.

[0139] The above-mentioned concentrations of PEG-phospholipid molecules can also be used in organ preservation solutions containing PEG-phospholipid molecules.

[0140] The PEG-phospholipid molecules are preferably administered in the form of a PEG-phospholipid solution. The solution comprising the PEG-phospholipid molecules can be, for example, saline, a buffered aqueous solution, or an organ preservation solution. Illustrative but non-limiting examples of aqueous buffer solutions that can be used include phosphate buffered saline (PBS) and citrate solutions.

[0141] Illustrative but non-limiting examples of organ preservation solutions that can be used according to embodiments include histidine-tryptophan-ketoglutarate (HTK) solution, citrate solution, University of Wisconsin (UW) solution, Collins solution, Celsior solution, Kyoto University solution, and Institut Georges Lopez-1 (IGL-1) solution. In certain embodiments, the organ preservation solution is HTK solution.

[0142] The above-described embodiments of surface antigens and PEG-phospholipids also apply to this aspect of the embodiments.

[0143] Example

[0144] Example 1

[0145] This example investigates the protective effects of specific PEG-phospholipids by shielding different cell types with PEG-phospholipid coatings and evaluating their blocking effects on antibody binding to surface antigens.

[0146] Materials and methods

[0147] Production Process

[0148] In this example, polyethylene glycol-phospholipid (PEG-phospholipid) with 5 kDa PEG or 5 kDa free PEG (NOF Corp., Japan) was used. PP-050CN, N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, sodium salt, NOF Corp., Japan) was used as received. Free PEG (5 kDa) was prepared from α-N-hydroxysuccinimidyl-ω-maleimidopoly(ethylene glycol) (NHS-PEG-Mal, Mw: 5,000, NOF) by reacting NHS-PEG-Mal with glycine and cysteine ​​to inactivate the NHS and maleimide groups, and then purified on a spin column.

[0149] Cell Type

[0150] Human red blood cells were isolated from healthy human donors. They were pre-selected for a specific blood type, and only individuals with exposed blood type B antigens were used. Human blood was drawn from the donor using a vacuum blood collection tube (5 mL, EDTA-2Na treated, TERUMO Co., Tokyo, Japan). After removing the plasma and buffy coat by centrifugation (15 min, 2500 × g, 3 times), the red blood cells were resuspended in cold PBS.

[0151] Caucasian acute lymphoblastic leukemia cell line (CCRF-CEM) was purchased from Health Science Research Resources Bank (Tokyo, Japan). CCRF-CEM cells were cultured in RPMI-1640 medium (containing 10% heat-inactivated fetal bovine serum, 50 IU / mL penicillin and 50 μg / mL streptomycin) (37°C, 5% CO2).

[0152] Coating effect of PEG-phospholipids on antibody response using human erythrocytes

[0153] This example was approved by the Ethics Committee of the University of Tokyo (KE17-13). Human red blood cells (RBCs) were isolated from whole blood of type B donors and suspended in phosphate-buffered saline (PBS). RBC pellets (5 × 10 7RBCs were incubated with PEG-phospholipids (20 μl, 2 mg / ml in PBS) or PBS (50 μl, as a control) for 30 min at room temperature (RT, 20-25°C) and gently mixed. After washing twice with PBS by centrifugation (120 × g, 4°C, 1 min), Alexa488-labeled anti-B blood group antigen antibody (10 μl, used without dilution, B blood group antigen antibody [HEB-29], GeneTex) or PBS (10 μl) were mixed with the treated RBCs for 10 min at room temperature. After washing with PBS by centrifugation (120 × g, 4°C, 1 min), RBCs were resuspended in PBS (1 ml) for flow cytometry measurements. All samples were analyzed on an Accuri C6 flow cytometer (BD), and additional controls in the form of isotype controls and unstained controls were run. Post-analysis processing was performed in FlowJo (BD).

[0154] Coating effect of PEG-phospholipids for antibody response using CCRF-CEM

[0155] From the cell culture medium (1×10 6 CCRF-CEM cells (1×10 cells) were collected and washed with PBS by centrifugation (250×g, 3 min, RT). 6 Cells) were incubated with PEG-phospholipids (50 μl, 2 mg / ml in PBS), 5 kDa unconjugated PEG (50 μl, 2 mg / ml in PBS) or PBS (50 μl, as a control) at room temperature for 30 minutes and gently mixed. After washing twice with PBS by centrifugation (200×g, 4°C, 3 minutes), three FITC-labeled antibodies: FITC-anti-human CD52 from BioLegend (400 μg / ml, 40 μl), FITC-anti-human CD4 from BioLegend (200 μg / ml, 40 μl) or Alexa488-labeled anti-human CD8 from GeneTex (200 μg / ml, 40 μl, Alexa488 was labeled by a labeling kit) or PBS (40 μl) were mixed with the treated CCRF-CEM at room temperature for 15 minutes. As a control, CCRF-CEM was treated with 2 mg / ml PEG (5 kDa in PBS) solution and incubated with FITC or Alexa488 labeled antibodies. After washing with PBS by centrifugation (200 × g, 4 ° C, 3 minutes), CCRF-CEM was resuspended with PBS (1 ml) for flow cytometry measurement. Samples were analyzed on a flow cytometer (BD LSR II, BD Biosciences). Post-analysis processing was performed in FlowJo (BD).

[0156] Inhibition of complement-mediated lysis by PEG-phospholipid coating

[0157] To investigate whether PEG-phospholipids can prevent complement-mediated lysis, RBCs from 13 different donors that were typed for Rh complex and ABO antigens were used. RBCs were isolated and pre-incubated with different concentrations of PEG-phospholipids, free PEG or PBS as described above. The cells were then washed with PBS (800g × 5 minutes, room temperature) (and the supernatant was stored for analysis) and incubated with human serum (complement system is active) for 20 minutes at 37°C. They were then centrifuged again (800g × 5 minutes) and the supernatant was collected for hemolysis analysis. RBCs were analyzed for complement fixation (cells were incubated with FITC-labeled anti-C3c antibody for 10 minutes). Red blood cells were resuspended with PBS (1 mL) for flow cytometric measurements. All samples were analyzed on an Accuri C6 flow cytometer, and additional controls in the form of isotype controls and unstained controls were run. Post-analysis processing was performed in FlowJo (BD). The absorbance of the supernatant at 540 nm was analyzed in a variable wavelength detection plate reader Synergy HTX. RBCs lysed by osmotic pressure were run in parallel as a positive control. The background absorbance of PBS without cells at 540 nm was subtracted, and then the absorbance difference between cells coated with PEG-phospholipids or PBS was calculated.

[0158] result

[0159] FITC-labeled PEG-phospholipids and CCRF-CEM cells (5×10 6 ) studied cell surface modification. Cells were incubated with different concentrations of FITC-labeled PEG-phospholipids (0.1, 0.5, 1.0, and 2.0 mg / ml in PBS) or PBS without PEG-phospholipids (as a control). Cells were incubated at room temperature for 10, 20, 30, or 60 minutes with gentle mixing. After removing excess FITC-labeled PEG-phospholipids, the remaining PEG-phospholipids on the cell surface were quantified by flow cytometry. The binding of FITC-labeled PEG-phospholipids to the cell surface depends on the incubation time and concentration, see Figure 2 The binding of FITC-labeled PEG-phospholipids reached a plateau after 30 minutes of incubation. In addition, no difference in the binding of FITC-labeled PEG-phospholipids was observed at concentrations above 0.5 mg / ml. In summary, these results indicate that FITC-labeled PEG-phospholipids can rapidly coat cell membranes and that the reaction is saturable.

[0160] CCRF-CEM cells were incubated with PEG-phospholipids (2 mg / ml in PBS), free PEG (5 kDa, equivalent molecular weight for synthesis of PEG-phospholipids), or PBS (vehicle control) for 30 minutes at room temperature. After removing excess PEG-phospholipids, FITC-labeled antibodies against surface antigens of different sizes, CD52, CD4, and CD8, were added. Samples were analyzed on a flow cytometer. Antibodies against CD52, a small surface antigen (about 1 nm), were completely blocked by PEG-phospholipids ( Figure 3A The binding ability of CD8 antibody was reduced by PEG-phospholipid, but it was not completely blocked ( Figure 3A ). Based on the crystal structure of the non-membrane portion, the size of CD8 was estimated to be approximately 5-10 nm. Finally, given that the size of the antigen (15 nm) is larger than the size of the PEG-phospholipid (estimated to be approximately 6 nm), the CD4 antibody was not blocked by the PEG-phospholipid, as expected ( Figure 3A ). Free PEG does not significantly affect the antibody's ability to bind to any surface antigen.

[0161] Blood group antigens are important surface antigens in the field of transplantation. The binding capacity of fluorescently labeled anti-B blood group antigen antibodies after PEG-phospholipid coating was evaluated using flow cytometry. Red blood cells (RBCs) were isolated from healthy human donors of type B blood and incubated with PEG-phospholipids (2 mg / ml in PBS) or PBS (control) for 30 minutes at room temperature. The PEG-phospholipid coating on RBCs was evaluated for its effective reduction in binding capacity by incubating the coated RBCs with plasma containing complement factors and anti-B blood group antigen antibodies for 20 minutes at 37°C, see Figure 3B . Complement fixation (using anti-C3c antibody) and lysis were studied using flow cytometry. PEG-phospholipids reduced complement-mediated RBC lysis in AB0 mismatched donors in a dose-dependent manner compared to untreated controls. ( Figure 3C ).

[0162] PEG is a linear polymer and the molecular weight is related to the length of the polymer, resulting in protrusion from the cell membrane. The PEG in PEG-phospholipid has a mass of 5kDa and a size of approximately 6nm, forming a 6nm PEG layer when anchored in the membrane. The sizes of the B blood group antigen, CD52, CD8, and CD4 on the cell surface are approximately 1nm, 1nm, 5-10nm, and 15nm, respectively. Therefore, this is consistent with size-dependent inhibition. The binding of the antibody to CD4 is more significantly inhibited than that to CD8. The stem region of CD8 causes the molecule to protrude less from the membrane, even though CD8 and CD4 are of similar size, see Figure 4 .

[0163] Example 2

[0164] This example investigates the effect of PEG-phospholipids in sequestering rhesus factors D, C, c, E, and e on erythrocytes.

[0165] Materials and methods

[0166] Whole blood samples (one O Rh+ blood sample and two A Rh+ blood samples) from the blood center were centrifuged at 2500 rpm for 10 minutes at room temperature (20-25°C) in Eppendorf tubes in an Eppendorf 5810R centrifuge, and the plasma was removed and discarded. The cell fraction was subjected to three washing steps in a 50 ml falcon tube. Each washing step consisted of adding 45 ml of phosphate buffered saline (PBS) to 1 ml of the cell fraction, followed by centrifugation at 2500 rpm for 10 minutes at room temperature.

[0167] 100 μl of the cell suspension was mixed with 900 μl PBS and 1000 μl PEG-phospholipid (4 mg / ml, polyethylene glycol-phospholipid (PEG-phospholipid) with 5 kDa PEG in PBS, PP-050CN, N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, sodium salt, NOF Corp., Japan) was mixed and coated with 2 mg / ml PEG-phospholipids (final concentration) or 1000 μl PBS as a control. The erythrocyte samples were incubated at 37°C for 30 minutes in a rotating incubator in a POL-EKO laboratory incubator. The erythrocyte samples were washed three times with 2 ml PBS and centrifuged at 2500 rpm for 5 minutes at room temperature in a Heraeus Biofuge Pico centrifuge.

[0168] Then the washed red blood cell samples were subjected to agglutination test and Rh phenotype analysis. More specifically, EDTA blood was drawn and RBC was collected and washed three times in PBS (1 mL blood in 45 mL PBS). Then, 100 μL RBC aliquots were incubated with 1.9 mL PEG-phospholipids in PBS or only with PBS (control) at 37°C in a rotating incubator for 30 minutes. RBC was washed three times with PBS (2 mL) and suspended to 50% hematocrit. Subsequently, according to the manufacturer's instructions, Diaclon ABO / Rh IDcards (Biorad) were used to perform blood typing tests on the RBCs and control RBCs treated.

[0169] result

[0170] Figures 5A to 7B A 0Rh+ blood sample was presented ( Figure 5A and 5B ) and two A Rh+ blood samples ( Fig. 6A and 6B , 7A and 7B). Figure 5B , 6B As can be clearly seen in 7A and 7B, the untreated control resulted in agglutination. However, treatment of erythrocytes with PEG-phospholipids masked the rhesus factor antigen on the cell surface, thereby inhibiting agglutination ( Figure 5A , 6A and 7A).

[0171] Therefore, PEG-phospholipids can mask the rhesus factor antigen on the cell surface of erythrocytes, thereby preventing erythrocyte agglutination.

[0172] Example 3

[0173] This example investigates the effect of PEG-phospholipids in masking cell membrane proteins of human umbilical vein endothelial (HUVEC) cells.

[0174] Materials and methods

[0175] Preparation of HUVECs

[0176] HUVEC cells were cultured in cell culture flasks (Thermofisher Scientific) and culture dishes (NUNC) with endothelial cell culture medium (Promocell) containing supplements. Cells were separated using trypsin EDTA buffer for flow cytometry analysis (BD accuri C6 Serial No. 5173). Cells were washed once with PBS (10 mL) by centrifugation (120 × g, 4 ° C, 3 minutes), and fresh culture medium was added to the separated cells.

[0177] Masking of antigens on HUVEC by coating with PEG-phospholipids

[0178] 100 μL HUVEC cell pellet (5×10 4 cells) in 0.5 mg / mL PEG-phospholipid solution (final concentration, polyethylene glycol-phospholipid (PEG-phospholipid) with 5 kDa PEG in PBS, PP-050CN, N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, sodium salt, NOF Corp., Japan) or PBS at room temperature for 45 minutes. Then, the cells were incubated with the following for 15 minutes at room temperature: with 5 μg / mL FITC-labeled antibodies: CD31 antibody (5 μg / ml) or isotype control Ab-FITC (BD biosciences) or with rabbit anti-von Willebrand factor (vWF), with rabbit IgG as a control, all visualized by Alexa 488 goat anti-rabbit antibody, as shown in Table 1.

[0179] In addition, HUVEC cells were incubated with PEG-phospholipids (0.5 mg / mL), 10 mM free PEG (5 kDa) or PBS (control) at room temperature for 45 minutes, then washed with PBS and incubated in human serum for 30 minutes at 37°C with EDTA-plasma as a control, both diluted 1:50 in PBS. After washing, the lectin pathway recognition molecules lectin-11 (CL-11) and mannan binding lectin (MBL) were detected using FITC-labeled and isotype control antibodies given in Table 1. For both analytes, values ​​are presented after subtracting the binding level in EDTA plasma. In addition, FITC-labeled concanavalin A (a lectin with broad specificity) was incubated with coated and native HUVEC (not exposed to plasma) at a concentration of 50 μg / ml.

[0180] After incubation with detection antibodies, cells were washed with PBS. All samples were analyzed on an Accuri C6 flow cytometer and unstained cells were used to gate the endothelial cell population. 10,000 events were recorded and additional controls in the form of isotype controls and unstained controls were run in parallel. Post-analysis processing was performed in FlowJo.

[0181] Table 1 - Antibodies

[0182]

[0183] result

[0184] HUVEC cells treated with PEG-phospholipids were incubated with human plasma and then assessed for binding to FITC-labeled antibodies against CL-11 or to the lectin concanavalin A without exposure to plasma. In both cases, PED-lipids significantly reduced binding ( Figure 8 ).

[0185] PEG-phospholipid coating induced modest CD31 masking (<20%), did not reduce the detection of vWF, and resulted in a significant reduction in MBL binding to human serum (25-30%), see Fig. 9 .

[0186] The mechanism of induction of ischemia-reperfusion injury (IRI) has not been determined, but it has been shown that MBL, CL-11, MASP-2 and natural IgM antibodies bind to ligands on ischemic cells, thereby initiating IRI. We hypothesize that after reperfusion, the PEG-phospholipid coating shields the endothelial and tubular cell membranes by hindering cell membrane proteins from protruding and binding to plasma proteins in the blood of the kidney graft. Our data confirm this concept, as PEG-phospholipids can effectively shield small surface antigens such as CD52 and Rh antigens, see Examples 1 and 2, which extend about 1 nm from the surface. In addition, CD8, which ranges between 5-10 nm based on the crystal structure of the non-membrane part, was partially blocked by the PEG-phospholipid coating, while the PEG-phospholipid layer did not extend to cover taller antigens such as CD4, which extends an estimated molecule of 15 nm from the membrane, see Example 1. Antibodies to CD31 and vWF (extending 15 nm and 30 nm from the surface, respectively) were also not affected. These results are consistent with the fact that PEG-phospholipids have 5 kDa PEG chains and theoretically extend 6 nm from the cell membrane ( Figure 4 ).

[0187] Example 4

[0188] This example studies the in vivo pharmacokinetics of PEG-phospholipids in porcine kidney.

[0189] Materials and methods

[0190] Preparation of PEG-phospholipid derivatives

[0191] PEG-phospholipids were purchased from NOF corporation, Tokyo, Japan ( PP-050CN, N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, sodium salt). Fluorescein labeling was performed by conjugating 5FAM-GC-OH (5-carboxyfluorescein) to Mal-PEG-phospholipid. First, Mal-PEG (5kDa)-DPPE was synthesized by combining aN-hydroxysuccinimidyl-w-maleimido poly (ethylene glycol) (180 mg, NHS-PEG-Mal, Mw: 5kDa, NOF), triethylamine (50 μL) and DPPE (26 mg) with dichloromethane and stirring at room temperature (RT) for 36 hours. Mal-PEG-phospholipid (190 mg, 95% yield) was obtained by precipitation with diethyl ether as a white powder. 5FAM-GC-OH (FAM-GC) was conjugated to Mal-PEG-phospholipid. In short, 107 μL of DMSO containing FAM-GC (10 mg / mL) was mixed with 1 mL of Mal-PEG-phospholipids (10 mg / mL in PBS) at room temperature for 24 h. Before being used for cell modification, the PEG-phospholipids (FAM-PEG-phospholipids) bound to fluorescein-GC were purified using a spin column (Sephadex G-25, GE Healthcare, Buc kinghamshire, UK). The resulting labeling was approximately 0.7 mol FAM / mol PEG-phospholipids.

[0192] Biotin-PEG-DPPE (biotin-PEG-phospholipid) was synthesized by mixing poly(ethylene glycol) (N-hydroxysuccinimide 5-pentanoate) ether 2-(biotinamino)ethane (biotin-PEG-NHS, Mw: 5000Da, from NOF, 180mg) and DPPE (20mg) with triethylamine (50μL) and dichloromethane (4mL) and stirring at room temperature for 48 hours. Precipitation with diethyl ether gave biotin-PEG-lipid (165mg; 80% yield) as a white powder. All PEG-phospholipid preparations were used at a final concentration of 2mg / mL.

[0193] Culture of CCRF-CEM cells

[0194] The CCRF-CEM cell line was used in this experimental setting due to its floating characteristics, and thus the use of trypsin during the splitting process can be avoided, which is beneficial because trypsin may affect the PEG-phospholipid coating on the cell surface. The CCRF-CEM cell line was purchased from Health Science Research Resources Bank (Tokyo, Japan). CCRF-CEM cells were cultured in RPMI-1640 medium (containing 10% heat-inactivated fetal bovine serum, penicillin 50 IU / mL and streptomycin 50 μg / mL) (37°C, 5% CO2).

[0195] Retention time, cell growth and viability after PEG-phospholipid modification

[0196] CCRF-CEM cells (3×10 6 Cells were centrifuged (120 × g, 4 ° C, 3 minutes) and washed once with PBS (3 mL). The cell pellet was suspended in FAM-PEG-phospholipids (50 μl, 2 mg / mL in PBS) or PBS (50 μL, as a control) for 30 minutes at room temperature with gentle stirring. The cells were washed once with PBS (10 mL) by centrifugation (120 × g, 4 ° C, 3 minutes), and the cell pellet was suspended in RPMI 1640 (1 mL). The coated cells were seeded in 6-well plates (5 × 10 5 Cells / mL in 5 mL RPMI 1640) were added and viability and cell number were calculated using a cell counter at 0, 1, 2, 4, and 7 days of incubation (dead cells were stained with trypan blue). The binding of FAM-PEG-phospholipids bound to the cell surface was assessed at the same time points by confocal laser scanning microscopy and flow cytometry.

[0197] Distribution and separation of PEG-phospholipids in blood vessels and renal tubules in vivo

[0198] Example 5 gives complete information of donor pigs and recipient pigs. Donor kidneys were treated with 10-15mL of a 2mg / mL biotin-PEG-phospholipid solution. Four recipient pigs were transplanted with kidneys treated with biotin-PEG-phospholipids. Throughout the study, their native kidneys were not removed and retained in the animals. Four recipient pigs were euthanized after 12, 24, 48, and 72 hours, respectively, and biopsies were taken from the kidneys treated with biotin-PEG-phospholipids and one of the native kidneys at the time of euthanasia. Cryosections (4 μm thick) were incubated at room temperature in Alexa488-streptavidin (GE Healthcare, 1:500) for 10 minutes. The sections were analyzed by laser scanning confocal microscopy (LSM510, META, Carl Zeiss, Germany). The slides were visualized using a Zeiss Axio Imager A1 microscope.

[0199] result

[0200] Dose-responsive binding of PEG-phospholipids to the cell surface

[0201] To optimize the binding of PEG-phospholipids to cells, a non-adherent cell line (CCRF-CEM) was used. CCRF-CEM cells were incubated with FAM-PEG-phospholipids (up to 2.0 mg / mL) and the amount of bound PEG-phospholipids was determined by flow cytometry. The binding of PEG-phospholipids to the cell surface depends on the incubation time and concentration ( Figure 2 The binding of all concentrations of PEG-phospholipid reached a steady state after 30 min, and no significant increase in the binding of FAM-PEG-phospholipid was observed at concentrations ≥ 0.5 mg / mL FAM-PEG-phospholipid, confirming the rapid and saturated coating of the cell membrane.

[0202] In vivo and in vitro separation and half-life of PEG-phospholipids

[0203] The dissociation of FAM-PEG-phospholipids from CCRF-CEM cells in vitro over time was investigated by flow cytometry and confocal microscopy. Fig.10 ). The fluorescence signal was minimal after 2 days of culture and was no longer detectable after 4 days of culture. PEG-phospholipid binding was limited to the cell membrane and was not taken up by the cells.

[0204] The kinetics of PEG-phospholipid attachment to the renal parenchyma in vivo were studied in a porcine survival model (see Example 5), in which pigs were transplanted with grafts treated ex vivo with biotin-PEG-phospholipid. The animals were subsequently euthanized. The half-life of PEG-phospholipid attachment to the kidney was calculated by fluorescence analysis using Alexa488-streptavidin by confocal microscopy. The curve was fitted to the data points using a one-phase exponential decay model, and the half-life of PEG-phospholipid binding to the renal parenchyma was calculated to be approximately 14 hours (SD: 8-26) ( Fig.11 The recipients' native kidneys were also preserved and analyzed to estimate systemic leakage of PEG-phospholipids, which proved to be very low and only reliably detected after 1 hour. In contrast, FAM-PEG-phospholipids ( Fig.12 ).

[0205] By monitoring the fluorescence of PEG-phospholipids bound to cells in vitro, it was concluded that there was a decrease in fluorescence intensity during the observation period, indicating that the PEG-phospholipids were dissociated from the endothelium. In vitro, the PEG-phospholipids were completely dissociated after 48 hours. In vivo in ANSM, it was demonstrated that within 6 hours after transplantation, the fluorescence seemed to migrate from the glomerulus to the tubular system. These data are supported by the fact that in survival studies, FAM-PEG-phospholipid fluorescence was detected within 12-24 hours after reperfusion, which completely disappeared after 48 hours. t was calculated. 1 / 2 The fluorescence was observed in the urine for 14 hours, supporting the excretion of the PEG-phospholipid constructs via the kidneys.

[0206] Example 5

[0207] This example tests PEG-phospholipids in three different porcine transplant models: the acute non-survival model (ANSM), the allogeneic survival model (SM), and the clinical-like allogeneic survival model (CLSM), without immunosuppression, for up to four days.

[0208] Materials and methods

[0209] Preparation of PEG-phospholipid derivatives

[0210] PEG-phospholipids were prepared as described in Example 4.

[0211] Routine clinical chemistry markers

[0212] Before surgery in both long-term survival studies (SM and CLSM), samples were collected from donors and recipients in EDTA tubes for analysis of total and differential leukocyte counts and hematology (EPK, Hb, EVF, MCV, MCHC, reticulocytes, platelets). Plasma samples were analyzed for aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), γ-glutamyltransferase (GT), glutamate dehydrogenase (GLDH), and creatinine at the Section of Clinical Chemistry, SLU, Uppsala.

[0213] During and after surgery, systemic blood was collected for up to 4 days and analyzed for creatinine, sodium, potassium, and phosphate (Department of Clinical Chemistry, Uppsala University Hospital).

[0214] Complement and coagulation activation markers in EDTA plasma

[0215] The levels of complement activation products C3a and soluble C5b-9 (sC5b-9) in porcine plasma were assessed using commercially available kits according to the manufacturer's instructions (ABIN2543272 and ABIN6202276; Antibodies-online.com). Human C3a was measured as follows: anti-human C3a mAb 4SD17.1 was used for capture and biotinylated polyclonal rabbit anti-C3a antibody was used for detection, and human sC5b-9 was measured as follows: mAb anti-human neo-C9 aEII (Bioporto Diagnostics A / S, Hellerup, Denmark) was used for capture and polyclonal sheep biotinylated anti-Hu-C5 antibody (BP373, OriGene, Herford, Germany) was used for detection.

[0216] TAT in both human and porcine plasma was measured as follows: capture was performed using anti-human thrombin monoclonal antibodies and detection was performed using HRP-coupled anti-human antithrombin (AT) antibodies (Enzyme Research Laboratories, South Bend, IN, USA). The FXIIa-C1INH complex was analyzed by sandwich ELISA, essentially as described in 6, using goat anti-human FXII polyclonal antibodies (Enzyme Laboratories) to capture and goat anti-C1INH antibodies (EnzymeReseach Laboratories) to detect. It should be noted that the assays used for human and porcine TAT and FXIIa-C1INH complexes here are completely cross-reactive, while those used for C3a and sC5b-9 are not.

[0217] Cytokines and chemokines

[0218] Multiplex protein analysis of 12 cytokines / chemokines was performed using a porcine-specific kit using multiplex Luminex xMAP technology (Millipore Corporation, Billerica, MA, USA): interferon-γ (INFγ), interleukin IL-1b, IL-2, IL-1a, IL-1RA, IL-4, IL-6, IL-10, IL-18, IL-8, IL-12, and TNF. Plasma was incubated with reagent-specific color magnetic beads and then with detection antibodies and streptavidin-phycoerythrin (Millipore Corporation). Plates were measured using a MAGPIX instrument (Luminex Corporation, Austin, TX, USA). Raw data [median fluorescence intensity (MFI)] were converted to protein concentration (ng / mL) using a standard curve.

[0219] Additionally, TNF, IL-1b, IL-6, and tissue factor (TF) were quantified in plasma by immunoassay using a GyroLab workstation (Gyros, Uppsala, Sweden), and the presence of these compounds as well as IFNγ in biopsies was confirmed by PCR (see below).

[0220] Renal biopsy

[0221] Detection of PEG-phospholipids by tissue fluorescence

[0222] Cryosections (4 μm thick) of kidneys treated with biotin-PEG-phospholipid and control kidneys were incubated in Alexa488-streptavidin (GE Healthcare, 1:500) for 10 minutes at room temperature. The sections were analyzed by laser scanning confocal microscopy (LSM510, META, Carl Zeiss, Germany).

[0223] Immunohistochemistry

[0224] Porcine kidney tissue was cut into paraffin sections (3-5 μm), dewaxed in xylene, and rehydrated with a series of graded ethanol and distilled water. For IHC staining, heat-induced antigen retrieval was performed by boiling the sections in sodium citrate buffer (pH 6), and the sections were blocked with 10% normal goat serum (Jackson Immunoresearch) before incubation with primary antibodies: anti-MAC (abcam ab66768); anti-C3bα chain (Bioss bs-4873R); anti-C4d (abcam ab64157), anti-C5aR (AcrisAP06509PU-N), anti-HO1 (abcam ab52947), anti-CSE (abnova H00001491-M01), anti-nitrotyrosine (Merck Millipore AB5411), anti-NOS2 (Santa Cruz sc-651), and detected by DAKO Real DetectionSystem alkaline phosphatase red (Dako). Sections were counterstained with Mayer's hematoxylin (Sigma #51275). Control staining was performed with nonspecific rabbit IgG (Dako #X0936). Slides were visualized using a Zeiss Axio Imager A1 microscope equipped with a ×10 objective (magnification 100×). Multiple randomly selected 800,000 μm 2 The staining intensity of the sections was quantified. Data are presented as the mean sum of the density in red.

[0225] Quantitative RT-PCR of cytokines in tissue samples

[0226] Snap-frozen renal wedge biopsies were pulverized in a QIA grinder (Qiagen, Uppsala, Sweden) and stored at -70°C. Total RNA extraction and cDNA synthesis were performed using the RNAeasy Mini kit (Qiagen, Holden, Germany) and the Superscript II Reverse Transcriptase kit (Invitrogen, Stockholm, Sweden), respectively. cDNA sequences for all porcine genes were obtained from Genbank. All primers were provided by Invitrogen. Gene expression was determined by RT-PCR. The specificity of PCR products was assessed by electrophoresis on 2% agarose gels. mRNA expression was normalized to β-actin, and quantitative values ​​were obtained from the threshold cycle number (Ct), and the fold change of expression was assessed using the ΔΔCt method. The selected analytes included the proinflammatory cytokines IL-1b, IL-6, IFNγ and TNF, and TF.

[0227] NET Analysis

[0228] Dewaxed renal tissue samples were fixed with 0.15 mol / L sodium cacodylate, pH 7.4 cacodylate buffer containing 2.5% glutaraldehyde for 30 minutes at room temperature and used for the detection of NETs. After fixation, the samples were washed with cacodylate buffer and dehydrated with an increasing ethanol series (10 minutes / step) from 50% (volume / volume) to absolute ethanol. The specimens were critically stained in carbon dioxide with absolute ethanol as an intermediate solvent. The specimens were examined using a HITACHI SU3500 scanning electron microscope at the MBio Microscope Facility of the Department of Biology. The location of individual target molecules was analyzed at high resolution by ultrathin sectioning and transmission immunoelectron microscopy. The coverslips with the specimens were embedded in Epon 812 and cut into 50 nm thick ultrathin sections using a diamond knife in an ultramicrotome. To quantify the NET area, the characteristic reticular fiber structure was first identified at high magnification. Quantitative NET surface area assessment was performed using Adobe Photoshop CS5. Briefly, the number of pixels per square micrometer was determined using the Ruler Tool. The NET area was then converted to the number of pixels using the Magic Wand Selection Tool. Thus, the fraction of the NET area relative to the entire area of ​​a given electron micrograph was calculated.

[0229] Urine

[0230] In the acute non-survival model, the ureters of both kidneys were catheterized and continuous urine samples were collected for 6 hours. The amount of fluorescein-labeled FAM-PEG-phospholipids in urine was quantified in samples added to black microplates (Thermo Scientific, 96FMaxisorb; black microplates; 43711) and measured using a fluorescence plate reader Synergy HTX with an excitation wavelength of 485 nm and an emission wavelength of 528 nm.

[0231] Experimental Design - In Vivo Pig Studies

[0232] The pig was chosen as a large animal model for allogeneic transplantation because its anatomy and physiology are very similar to those of humans. Specifically, the structure and function of the kidney are very similar to those of primate organs. The pig kidney is described as truly multinephrotic and multipapillary, with a calyceal system similar to that of humans. The blood supply is distributed laterally between the cranial and caudal poles, rather than longitudinally as in most other species. The pig has similar nephron types to humans, and the renal cytochrome enzymes (P450 3A, 2A, 2C) show similar activities to the human homologous enzymes. In addition, there are many examples of similar or identical genes encoding enzymes present in human and pig kidneys, such as fucosidase, galactosidase, prostaglandin 9-ketoreductase, and dipeptidyl aminopeptidase IV. In addition, there are considerable similarities between the human and pig immune systems, with >80% similarity in the parameters studied. The corresponding similarity in human and pig parameters is only about 10%.

[0233] Three porcine allogeneic transplant models

[0234] To investigate the effects of PEG-phospholipid coatings in porcine allografts, an acute non-survival model (ANSM), an allogeneic survival model (SM), and a clinical-like allogeneic survival model (CLSM) were used in addition to in vivo studies to investigate tissue distribution and segregation (Example 4). Samples: Plasma, biopsies, and urine were collected as indicated in the sections describing each model below and analyzed as described above.

[0235] Table 2 - Summary of the four allogeneic transplant settings

[0236]

[0237] Porcine Acute Non-Surviving Transplantation Model (ANSM)

[0238] The study was approved by the Committee on Ethics of Animal Experiments in Uppsala, Sweden (Dnr C175 / 12).

[0239] Twelve pigs (Yorkshire x Landrace x Hampshire) were purchased from a traditional farm with high health pigs, aged 10-12 weeks and weighing 30-35 kg. The farm was supervised by pig experts at the SLU School of Veterinary Medicine. The animals were transported to the animal experimental facility of Uppsala University Hospital, where they immediately received non-survival transplants.

[0240] anaesthetization

[0241] Upon arrival at the facility, 2.2 mg / kg xylazine was administered intramuscularly (IM) Bayer, Leverkusen, Germany) and 6 mg / kg zolazepam-tiamine (Zoletil Virbac, Carros, France) was used for induction. Subsequently, the animals were fixed in the prone position. Peripheral intravenous catheters were inserted into both ears for TIVA anesthesia; midazolam 0.105 mg / kg / h (Midazolam Actavis 5 mg / mL, Actavis AB, Sweden), ketamine 28 mg / kg / h ( vet, 100 mg / ml Intervet AB, Sweden), fentanyl 3.5 μg / kg / h (fentanyl B. Braun 50 μg / mL, B. Braun Medical AB, Sweden), lactated Ringer's solution (Ringer's acetate, Fresenius Kabi AB, Sweden) about 10 mL / kg / hour and succinylated gelatin ( -B.40mg / mL, BraunMelsungen AG, Germany) infusion. A small incision was made in the trachea to expose the trachea and perform transtracheal intubation. The animals were mechanically ventilated with air containing 30% oxygen to obtain 5.0-5.5kPa CO2 (Servo-I Mechanical Ventilator, MAQUET, Medical Systems, US). A mean arterial pressure (MAP) of >60mm Hg was intended to ensure adequate organ perfusion.

[0242] Transplant surgery

[0243] We have developed a porcine transplantation model that allows both kidneys from a donor to be removed en bloc and implanted into a recipient animal. By performing a separate ex vivo PEG-phospholipid incubation of a randomly selected kidney from the en bloc package, this technology enables us to transplant the treated organ together with its perfectly matched control organ into a single recipient pig, which not only reduces the number of experimental pigs, but also minimizes experimental confounding variables.

[0244] The two kidneys were mobilized together with the suprarenal and infrarenal aortic trunks and the inferior vena cava to form a monolithic package consisting of the two kidneys and the corresponding ureters and renal vessels. The monolithic package was immediately removed and subjected to ectopic cold perfusion with cold HTK solution on a back table. Here, the time between donor in situ clamping and ectopic perfusion with cold HTK solution was less than 5 minutes, resulting in initial warm ischemia in this model. Subsequently, the monolithic package was refrigerated in HTK solution at 4 °C for 24 h. After removal, an overdose of sodium pentobarbital ( The donor pigs were euthanized by 400 mg / mL vet.

[0245] After storage, one kidney in each whole package was randomly selected for PEG-phospholipid incubation. The vein and artery of the contralateral kidney (control) and the vein of the selected kidney were clamped. A total of 3-5 mL of PEG-phospholipid solution at a concentration of 2 mg / mL was slowly infused into the selected kidney. The artery of the treated kidney was then clamped and the entire package was refrigerated in HTK at 4°C for another 40 minutes. After incubation and before implantation, excess PEG-phospholipid was rinsed from the treated kidney with HTK without removing the clamp from the control.

[0246] The recipient pig was processed and anesthetized as described above. The whole package was placed horizontally in the abdominal cavity. The distal ends of the vena cava and aorta of the graft were anastomosed to the contralateral ends of the recipient's vena cava and aorta, respectively. After release, the treated and control kidneys were reperfused sequentially (by delaying the release of the control kidney), and the effluent from the treated kidney was flushed away. This was done to prevent contamination of the control kidney with residual PEG-phospholipid solution in the aortic catheter. Both transplant ureters were catheterized separately to record urine output.

[0247] sampling

[0248] EDTA blood was collected from both graft veins at 1, 5, 15, 30, 60, 120, 240, and 360 minutes after reperfusion. Two wedge biopsies were taken from each graft at 1, 60, and 360 minutes after reperfusion. One biopsy was snap-frozen in liquid nitrogen for cytokine analysis and PEG-phospholipid assay, and the other was stored in 4% PFA and used for immunohistochemical studies. Total urine was collected 360 minutes after reperfusion.

[0249] SM and CLSM of the pig survival transplantation model

[0250] These studies were approved by the Committee for the Ethics of Animal Experiments in Uppsala, Sweden (Dnr C123 / 14). Five donor pigs and ten recipient pigs (of both sexes) were used in each of these studies (SM and CLSM). All pigs were certified SPF pigs (Yorkshire x Hampshire) and were maintained at SLU, Sweden. The pigs are raised at the university's pig farm. They are 8 weeks old when they arrive at SLU.

[0251] For SM studies, pigs were selected based on swine leukocyte antigen (SLA) class 1 typing in the following manner: Donor pigs were obtained from two litters and were not related to any recipient. Recipient pigs were siblings, paired based on SLA class 1 (see below). For CLSM studies, all recipient pigs were siblings and were not related to the donor, but these pigs were not SLA typed.

[0252] SLA typing by PCR-SSP

[0253] SLA typing was performed using complete primer sets specific for alleles of the three SLA class I loci, SLA-1, SLA-2, and SLA-3, and the three SLA class II loci, DRB1, DQB1, and DQA 8-10. Total genomic DNA was isolated from whole blood samples of 27 purebred pigs using the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma, St. Louis, MO, USA) according to the manufacturer's instructions. The typing PCR reactions contained 1× TopTaq TM Master mix (Qiagen GmbH, Hilden, Germany), 1× CoralLoad loading buffer (Qiagen), 0.2 pmol / μl α-actin positive control primer, 0.2 pmol / μl allele-specific primer (Eurofins Genomics Ebersberg, Germany) and 30 ng DNA in a total volume of 10 μl. A negative control without DNA was included for each pig typing to check for reagent contamination, and the set-up and electrophoresis were performed in a standard 96-well format. Thermocycling conditions on a T Gradient thermal cycler (Biometra, Goettingen, Germany) consisted of an initial incubation at 95°C for 2 minutes, followed by 30 cycles of 95°C for 15 seconds, 65°C for 20 seconds, and 72°C for 20 seconds. PCR products were electrophoresed at 150 V for 5 min in 1×TAE buffer containing 2.5% DNA grade agarose gel (Biozym Biotech Trading GmbH, Vienna, Austria) using a Micro SSP gel system (One Lambda, Canoga Park, CA, USA) and visualized after staining with GelStar™ (Lonza, Rockland, ME, USA). Interpretation of the results was based on the presence of allele-specific PCR products of the expected size in each lane.

[0254] Acclimation and training

[0255] The receptors are kept at approximately 2.5m 2 The donors were housed in separate pens where they could see and hear each other. Donors were housed together in the same pen. A 12:12 h light / dark schedule was used, and an infrared light (24 h) was placed in the corner of each pen. Straw and wood chips were used as bedding. The pigs were fed a commercial pig diet (SOLO 330, ), the dosage was according to the SLU regimen for growing pigs. Water was provided ad libitum. The pens were cleaned twice a day. The recipients underwent a 14-day socialization and training program, in which the pigs were trained to accept touching and palpation of the ears in preparation for pressure-free blood sampling from the ear vein. In addition, the animals were accustomed to the placement of an ultrasound transducer prosthesis in the abdomen to tolerate postoperative ultrasound examinations of the bladder and transplanted kidney. The pigs were also trained to step onto a spring scale, accept free-flowing urine sampling, and undergo a clinical examination including auscultation of the heart and lungs. After 14 days of acclimatization and training, the recipients weighed 32.4±2.2kg (mean±SD) and were ready for transplant surgery. The experiment lasted a total of three weeks.

[0256] Before surgery, blood samples were subjected to blood cell count and hematological analysis as described above to confirm that the donors and recipients in both studies were healthy.

[0257] Anesthesia and analgesia

[0258] According to Rydén et al. Nursing and training of pigs used in renal transplantation studies, Laboratory Animals (2020) 54(5): 469-478, the use of tiletamine-zolazepam in pig houses vet.Virbac,Carros,France) and medetomidine ( Anesthesia was induced with a mixture of 1 mg / mL of vet IM. Preoperatively, buprenorphine was given at a dose of 0.01 mg / kg BW IM, and benzylpenicillin procain ( vet.300mg / mL, Beohringer Ingelheim, Ingelheim, Germany) is given with a dose of 20mg / kg BW IM. The animal is covered with a blanket and transported to the preparation room, where oxygen saturation and pulse rate are measured. In order to prevent heat loss, socks are put on at the distal end of the claws and legs. An intravenous (IV) catheter (BD VenflonTM 20G, 32mm, BD Medical, Franklin Lakes, US) is placed in the auricular vein, and blood samples are collected to analyze complete blood cell count (CBC) and enzyme activity. Using a laryngoscope helps endotracheal intubation. Oxygen (4L / min) is delivered by a mask until the animal is connected to the anesthesia cycle. Anesthesia is maintained using isoflurane (IsoFlo vet. Orion Pharma Animal Health, Sweden) in an oxygen / air mixture (FIO2 0.3) from a rebreathing circuit, and all pigs are mechanically ventilated (FLOW-i anesthesia delivery system, MAQUET Medical Systems, US). Epidural morphine (Morfin Epidural Meda 2 mg / mL, Meda AB, Sweden) was administered at 0.1-0.12 mg / kg according to the protocol of Malavasi et al. 2006. Pigs received approximately 10 mL / kg / hour of IV infusion of lactated Ringer's solution (Ringer's acetate, Fresenius Kabi AB, Sweden) and 3 mL / kg of succinylated gelatin ( -B. 40 mg / mL, Braun Melsungen AG, Germany), followed by 3 mL / kg / hour. To achieve adequate arterial blood pressure (≥60 mmHg), dobutamine (DOBUTAMIN 250mg / 50ml, Carinopharm, Germany) was given as an infusion (5-15μg / kg / min). During anesthesia, circulatory and respiratory parameters were continuously monitored (AS / 3 anesthesia monitor, Datex-Ohmeda, Finland). Arterial blood pressure was measured intermittently with an oscillometric band using an inflatable cuff placed around the forelimb and connected to the monitor.

[0259] To allow for repeated blood sampling of recipient pigs, a polyurethane catheter (BD Careflow™ 3Fr 200 mm, BD Medical, US) was introduced into the jugular vein via the ear vein using the sterile Seldinger technique. The catheter was sutured to the ear with monofilament-coated polyamide (Supramid 2-0, B Braun Medical, Sweden) and bandaged with a bandage ( AS, Norway) coverage.

[0260] Donor surgery and graft management

[0261] SM study: The kidneys were removed en bloc using the same procedure as in the ANSM study. Here too, the kidneys were exposed to an initial warm ischemia of less than 5 minutes. After removal, an overdose of sodium pentobarbital ( The donor pigs were euthanized by 400 mg / mL vet.

[0262] After storage, kidneys were randomly assigned to receive PEG-phospholipids (15 mL, 2 mg / mL) or HTK solution at +4°C, injected through the renal artery after clamping the renal vein. The renal artery and vein remained clamped during the 40-60 minute incubation period. The SM study included 6 kidneys treated with PEG-phospholipids and 4 control kidneys.

[0263] CLSM study: In this study, kidney retrieval was similar to the standard surgical procedure for human organ procurement. Each donor was randomly assigned to PEG-phospholipid or HTK treatment. After warm dissection and mobilization of the kidney, the superior iliac aorta was clamped and a 12-French aortic cannula was inserted. Immediately after clamping the superior abdominal aorta, the kidney was flushed in situ by gravity infusion of PEG-phospholipid (250 mL, 2 mg / mL) or HTK (250 mL) solution via the aortic cannula. The blood was drained through an incision distal to the vena cava and cooled in situ by packing ice slurry around the kidney. After retrieval, the kidney was immersed in PEG-phospholipid or HTK solution and refrigerated at +4°C for 24 h. In contrast to the ANSM and SM studies, the kidney was not exposed to initial warm ischemia. The CLSM study included 5 PEG-phospholipid-treated kidneys and 5 control kidneys (Table 2).

[0264] Transplant surgery

[0265] The recipient pig received a single allogeneic kidney transplant. Through a 15-20 cm midline abdominal incision, the iliac vessels in the right iliac fossa were identified and carefully mobilized. The distal segment of the vena cava and the iliac artery (starting from its emergence from the aorta) were mobilized, and the surrounding lymphatic tissue was closed. The kidney graft was then placed in the right iliac fossa close to the iliac vessels. The renal vein and artery were trimmed and then sutured with a polypropylene 7 / 0 continuous suture ( Ethicon, US) was anastomosed to the recipient's right iliac artery and distal vena cava in an end-to-side manner. The ureterocystostomy was performed with 6-0 polydioxanone suture ( Ethicon, US) ureters were implanted into the bladder dome. Afterwards, bilateral nephrectomy of the native kidneys was performed. The midline incision was closed with Ethicon, US) fascial sutures and skin clips. No anticoagulants were given to the recipient. After the inguinal transplantation, urine was collected directly from the bladder by cystocentesis, showing that all transplanted kidneys began to produce urine soon after reperfusion. The samples were analyzed for proteinuria and hematuria by using urine sticks. The average duration of the operation was 2.5 hours (1.75-3.25 hours).

[0266] Postoperative Care

[0267] Towards the end of the surgery, isoflurane administration was discontinued, inspired oxygen concentration was increased (FiO2 1.0), and the pig was weaned from the mechanical ventilator. The animal was placed in a cage where it could be easily monitored continuously by staff. Oxygen supplementation was provided via a face mask. Heart rate, respiratory rate, oxygen saturation, and body temperature were monitored until the pig regained consciousness. At the end of anesthesia and for the remainder of the postoperative period, additional buprenorphine (0.03 mg / kg) was given intravenously after assessment of general condition and behavior. Enrofloxacin (2.6 mg / kg BW IM) was given the day after surgery. vet.100 mg / mL, Bayer) and benzylpenicillin procaine ( vet.300mg / mL, Boehringer Ingelheim). If necessary, pigs can be hand-fed fruits to stimulate appetite, support them to drink water, and assist them to stand and walk after surgery.

[0268] Sampling for SM and CLSM studies

[0269] During and after transplantation, EDTA blood was collected from the local renal vein at 0, 15, 30, and 60 minutes after reperfusion, and systemic blood samples were obtained 1, 2, 3, and 4 days after surgery.

[0270] Two wedge biopsies were taken from each graft before reperfusion, 15 minutes after reperfusion, and immediately after euthanasia.One biopsy was snap frozen in liquid nitrogen for cytokine analysis, and the other was stored in 4% PFA and used for immunohistochemical studies.

[0271] Clinical examination, including ultrasound evaluation of bladder and kidney transplants

[0272] Clinical presentation is assessed several times daily after surgery, and a thorough clinical examination is performed daily. The bladder is examined at 9 a.m. and 6 p.m. daily to determine whether the transplanted kidney is producing urine. If possible, free-flowing urine is collected and macroscopically assessed, and density, pH, blood, and protein are measured.

[0273] After transplantation, each kidney was examined once by ultrasound (Logiq e R6, GE Healthcare, Wauwatosa, USA) using linear (10 MHz) and curvilinear (4 MHz) probes. The length and echogenicity of the kidney and the definition of the corticomedullary were estimated. In addition, the presence of dilatation of the renal pelvic region was assessed. Color Doppler was used to assess blood flow in the kidney.

[0274] Autopsy

[0275] Four days after transplantation, pigs were sacrificed in a piggery pen by intravenous overdose of sodium pentobarbital (Euthasol vet. 400 mg / mL, Virbac).

[0276] All pigs (both donors and recipients) were necropsied by a veterinary pathologist at the Department of Biomedical Sciences and Veterinary Public Health, Department of Pathology, SLU, Uppsala.

[0277] Statistical analysis

[0278] Statistical analyses were performed using Prism macOS version 9.4.1 (458). One-sample, unpaired and paired, and multiple unpaired t tests were used as indicated in the figure legends. In addition, one-way ANOVA and two-way repeated measures ANOVA followed by multiple comparison tests without and with Bonferroni correction were used. The results of ANOVA are shown in the figure legends. The results of t tests and multiple comparison tests are presented in conjunction with specific data graphs as ns, *p<=0.05, **p<0.01, ***p<0.001, ****, and p<0.0001. Specific statistical methods are described in the figure legends.

[0279] result

[0280] PEG-phospholipid-mediated attenuation of ischemia-reperfusion-induced thrombotic inflammation in three porcine transplantation models

[0281] To assess the ischemic status of PEG-phospholipid treated kidneys compared to untreated kidneys, biopsies were collected after 1, 60, and 360 minutes in ANSM and stained for nitrotyrosine, HO-1, and INOS. No differences were found between treated and untreated kidneys, indicating that the tissues were in a similar ischemic state ( Fig.13 ).

[0282] In the ANSM, blood samples collected from the renal vein of each kidney were analyzed for thrombo-inflammatory biomarkers. Complement (C3a, sC5b-9), coagulation (TAT), and contact system (FXIIa-C1INH) markers were found to be significantly lower in the treated kidneys compared with the untreated kidneys over a 6-hour observation period ( Fig.14). Biopsies at 1 minute showed focal deposition of complement fragments C4d and C3b. Binding of C3b was significantly reduced in PEG-phospholipid treated kidneys, and there was a trend toward lower binding of C4d in treated kidneys ( Fig.15 This pattern was confirmed in SM, where C3a, sC5b-9, and TAT levels were significantly lower in blood samples from PEG-phospholipid-treated kidneys throughout the observation period (up to 4 days after transplantation) ( Fig.16 Renal biopsies performed at 5 minutes and 4 days after necropsy also showed lower C3b binding (two-way ANOVA) ( Fig.17 ). Although showing lower values, the results of CLSM confirmed these results (not shown).

[0283] In addition, scanning electron microscopy (SEM; Fig.18 ) analyzed neutrophil extracellular traps (NETs) as one of the drivers of thromboinflammation in renal allograft biopsies from ANSM. NET deposition was found to be primarily localized in the glomerular and tubular lumen at 1 minute after reperfusion. Quantification of renal NET deposition demonstrated that both glomerular and tubular NET deposition was significantly reduced in PEG-phospholipid treated kidneys compared to matched individual controls ( Fig.19 ).

[0284] PEG-phospholipid-mediated attenuation of ischemia-reperfusion-induced systemic inflammation in three porcine transplantation models

[0285] In ANSM, mRNA expression in renal biopsies of PEG-phospholipid treated animals was significantly increased compared to corresponding controls (RT-PCR, Fig. 20 ) and plasma concentrations of proinflammatory cytokines (IL-1β, IL-6, TNF) and TF in the renal vein ( Fig.21 In particular, IL-6 was significantly inhibited at most time points.

[0286] In SM, proinflammatory cytokines reflecting local inflammation 5 and 60 minutes after transplantation and systemic inflammation 4 days after transplantation were also assessed ( Fig. 22). An inflammatory response was detected after 5 minutes, although it was not significant and was only observed in untreated kidneys. After 60 minutes, this inflammatory response disappeared and a steady state was reached. Four days later, a strong response of most of the analyzed cytokines, except IL-8 and IL-1RA, was observed in pigs transplanted with untreated kidneys. Therefore, when the sustained effect of PEG-phospholipid ex vivo graft coating was investigated, the reduction of systemic inflammation 4 days after transplantation was obvious. Considering the short duration of PEG-phospholipid coating, this suggests that PEG-phospholipid-mediated inhibition of transient thromboinflammation triggered by IRI also affects persistent downstream systemic inflammation. The results of CLSM confirmed these results (not shown).

[0287] No toxicity or safety issues regarding clinical, laboratory, or pathological parameters were observed in any transplantation model, including differences in gross histology (hematoxylin staining) or macroscopic appearance between treated and untreated kidneys.

[0288] Effects of in vitro PEG-phospholipid treatment on the function of pig transplantation model

[0289] Renal function was assessed by diuresis after reperfusion in ANSM and by monitoring creatinine levels in blood samples collected from recipients in SM over time and found that despite very severe reperfusion injury and progressive renal insufficiency, pigs transplanted with PEG-phospholipid-coated grafts had significantly lower creatinine levels after transplantation than control grafts ( Fig.23 ). Consistent with this finding is a similar effect of the coating in CLSM, where IRI is less pronounced ( Fig.24 ).

[0290] The mechanism of IRI has not been determined, but it has been shown that MBL, CL-11, MASP-2, and natural IgM antibodies bind to ligands on ischemic cells, thereby initiating IRI. After reperfusion, the PEG-phospholipid coating of the present invention shields endothelial and tubular cell membranes by preventing cell membrane proteins from extending and binding to plasma proteins in the blood of the kidney transplant. The data confirm this concept because PEG-phospholipids can effectively shield small surface antigens such as CD52 and Rh antigens, which extend about 1 nm from the surface (see Example 1). In addition, CD8, which ranges between 5-10 nm based on the crystal structure of the non-membrane portion, was partially blocked by the PEG-phospholipid coating, while the PEG-phospholipid layer did not extend to cover higher antigens, such as CD4, which extends 15 nm from the estimated molecule of the membrane. In addition, antibodies against CD3135 and vWF (extending 15 nm and 30 nm from the surface, respectively) were not affected (see Example 3). These results are consistent with the fact that PEG-phospholipids have 5 kDa PEG chains and theoretically extend 6 nm from the cell membrane ( Figure 4 ).

[0291] To demonstrate the effects of PEG-phospholipids on IRI, non-surviving and surviving porcine transplant models were used, in which recipients were not immunosuppressed and followed for up to 4 days. In these in vivo transplant models, kidneys treated with PEG-phospholipids exhibited lower innate immune activation compared with untreated kidneys, as reflected by reduced plasma levels of TAT, FXIIa-C1INH, TF, C3a, and sC5b-9, as well as reduced deposition of C3b in renal biopsies. This suggests that the PEG-phospholipid constructs inhibit coagulation, contact, and complement system activation, and protect cell membranes from C3b deposition after reperfusion of recipient blood, all of which are hallmarks of IRI. Confirming these findings, in the ANSM study, the expression of proinflammatory cytokines (such as IL-1β, IL-6, TNF, and INFγ) as well as the formation of NETs were attenuated in kidneys treated with PEG-phospholipids, indicating a much lower thromboinflammatory response in the treated group. In the survival model, this pattern was much more pronounced after 4 days, with very low expression of all tested cytokines found in the treated group, while in the non-treated group, most cytokines were increased, except for IL-8 and IL-1RA. The profound effects suggest that PEG-phospholipids provide broad protection against IRI and systemic inflammation after transplantation, which is transmitted to the adaptive immune response, leading to humoral and cellular rejection. PEG-phospholipids also prevented both adaptive immune system and antibody-mediated rejection (AMR). The persistent and significant suppression of IL-6 in all three transplantation models supports this concept, as IL-6 / IL-6R signaling inhibition is considered a new therapeutic option for the prevention and treatment of allograft injury. Clinical trial evidence supports the use of IL-6 blockade for desensitization and treatment of AMR in renal transplantation (Curr Transplant Reports 8:1–14(2021), J Am Soc Nephrol 20:1032–1040(2009), Transplantation 101:32–44(2017)).

[0292] Example 6

[0293] This example evaluates the ability of PEG-phospholipids to block the binding of anti-human leukocyte antigen (HLA) antibodies to freshly isolated human peripheral blood mononuclear cells (PBMC) expressing HLA antigens. HLA antigens are proteins on the surface of all nucleated cells that present foreign peptides to T cell receptors on T cells in cellular immune responses. Antibodies to these structures are formed during allogeneic immune responses, such as in blood transfusions and transplants, and constitute the majority of all so-called donor-specific antibodies (DSA). These antibodies are the main cause of antibody-mediated rejection (AMR). In order to avoid this incompatible reaction, cross-matching is performed before transplantation, and patient serum that may contain DSA is mixed with PBMC from the donor. If DSA cannot recognize HLA antigens and the PBMC cells of the donor do not undergo lysis, the cross-matching is considered to be negative and can be transplanted. On the other hand, if the cross-matching result is positive, the transplanted organ must be transferred to other patients and matched (selected) with other patients for HLA antigens. When the cross-matching results of the donor and the recipient are negative, the transplant can be performed.

[0294] Materials and methods

[0295] To test PEG-phospholipids ( PP-050CN (N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, sodium salt, NOF Corp., Japan) blocks the binding of anti-HLA antibodies to HLA antigens, similar to the potential clinical setting in which we used human PBMCs from healthy donors to block HLA antigens.

[0296] Material

[0297] FITC mouse anti-human HLA-ABC; monoclonal (G46-2.6) (BD Pharmingen) Cat. No. 555552

[0298] Biotinylated mouse anti-human HLA class I antibody [W6 / 32] (Abcam) Catalog No. ab110665

[0299] PE-Streptavidin (BD Pharmingen) Cat. No. 554061

[0300] method

[0301] Cytiva TM Ficoll-Paque TMPLUS medium (Cytiva17-1440-02) was used to isolate PBMCs from whole blood. Briefly, whole blood was diluted in an equal volume of PBS and carefully layered on top of Ficoll paque and centrifuged at 800×g for 25 minutes. The turbid layer was separated from the top of Ficoll and washed again twice with PBS.

[0302] Cells were stained with FITC mouse anti-human HLA-ABC monoclonal antibody and biotin mouse anti-human HLA class I antibody [W6 / 32] (Abcam), followed by PE-streptavidin. The stained cells were analyzed by Beckman coulter cytoflex S (Biovis, Facility, IGP, Rudbeck Laboratory).

[0303] result

[0304] Fig.25 and 26 The results presented in show that both anti-HLA antibodies had a strong inhibitory effect on PEG-phospholipid-treated PBMCs, indicating that PEG-phospholipids mediated a strong masking effect. Therefore, PEG-phospholipids are able to mask HLA antigens on PBMCs and can be used to block the binding of DSA to such HLA antigens on organ transplants, thereby inhibiting AMR.

[0305] The above embodiments will be understood as some illustrative embodiments of the present invention. It will be appreciated by those skilled in the art that various modifications, combinations and changes may be made to the embodiments without departing from the scope of the present invention. Specifically, where technically possible, different partial solutions in different embodiments may be combined in other configurations. However, the scope of the present invention is limited by the appended claims.

Claims

1. A poly(ethylene glycol) phospholipid (PEG-phospholipid) molecule for selectively masking surface antigens of red blood cells and / or platelets in a blood product from a donor to inhibit the binding of antibodies to the surface antigens when the blood product is transfused into an uncross-matched or incompatible recipient, wherein the PEG chain of the PEG-phospholipid molecule has an average molecular weight selected in the range of 3000 to 10000 Da.

2. A poly(ethylene glycol) phospholipid (PEG-phospholipid) molecule for selectively masking surface antigens of an organ transplant from a donor, the organ transplant comprising red blood cells, platelets and / or endothelial cells, to inhibit antibody binding to the surface antigens and antibody-mediated rejection (AMR) associated with transplanting the organ transplant into an uncross-matched or incompatible recipient.

3. The PEG-phospholipid molecule for use according to claim 2, wherein the organ transplant is selected from the group consisting of kidney, liver, pancreas, heart, lung, uterus, bladder, thymus and intestine.

4. The PEG-phospholipid molecule for use according to claim 2 or 3, wherein the surface antigen is a human leukocyte antigen (HLA), preferably selected from the group consisting of HLA A, HLA B and HLA C.

5. The PEG-phospholipid molecule for use according to any one of claims 1 to 4, wherein the surface antigen is a rhesus factor, preferably selected from the group consisting of RhD, RhC, Rhc, RhE and Rhe.

6. PEG-phospholipid molecule for use according to any one of claims 1 to 5, wherein the surface antigen is a blood group antigen, preferably selected from the group consisting of A antigen and B antigen.

7. The PEG-phospholipid molecule for use according to any one of claims 1 to 6, wherein the surface antigen is a human platelet antigen (HPA), preferably selected from the group consisting of HPA-1, HPA-2, HPA-3, HPA-4, HPA-5, HPA6, HPA-9 and HPA-15.

8. The PEG-phospholipid molecule for use according to any one of claims 1 to 7, which, when anchored in a cell membrane, has an average extracellular length selected in the interval of 4 to 8 nm, preferably 5 to 7 nm and more preferably 6 nm.

9. The PEG-phospholipid molecule for use according to any one of claims 1 to 8, wherein the PEG-phospholipid molecule has formula (I): in n, m are independently selected from integers in the range of 10 to 16, preferably, n, m are independently 10, 12, 14 or 16, and more preferably, n=m=14; p is selected so that the PEG chains have an average molecular weight selected in the range of 3000 to 10000 Da and more preferably 5000 Da; and R is selected from the group consisting of H, methyl and C1-C4 alkylamine.

10. The PEG-phospholipid molecule for use according to any one of claims 1 to 9, wherein the PEG-phospholipid molecule has an average molecular weight determined by gel permeation chromatography selected in the interval of 5 to 7 kDa, preferably 5.5 to 6.6 kDa and more preferably 5.8 to 6.0 kDa.

11. The PEG-phospholipid molecule for use according to any one of claims 1 to 10, wherein the lipid part of the PEG-phospholipid molecule is 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (DPPE).

12. The PEG-phospholipid molecule for use according to any one of claims 1 to 11, wherein the PEG part of the PEG-phospholipid molecule has an average degree of polymerization selected in the interval of 105 to 125, preferably in the interval of 110 to 120 and more preferably in the interval of 114 to 116.

13. The PEG-phospholipid molecule for use according to any one of claims 1 to 12, wherein the PEG-phospholipid molecule is N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.

14. PEG-phospholipid molecule for use according to any one of claims 1 to 13, wherein the PEG-phospholipid molecule is not interconnected with other PEG-phospholipid molecules via any linker.

15. A blood product comprising red blood cells and / or platelets and poly(ethylene glycol) phospholipid (PEG-phospholipid) molecules anchored in the cell membranes of the red blood cells and / or platelets and masking surface antigens of the red blood cells and / or platelets, wherein the PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da.

16. The blood product according to claim 15, wherein the surface antigen is a rhesus factor, preferably selected from the group consisting of RhD, RhC, Rhc, RhE and Rhe.

17. A blood product according to claim 15 or 16, wherein the surface antigen is a blood group antigen, preferably selected from the group consisting of A antigen and B antigen.

18. The blood product according to any one of claims 15 to 17, wherein the surface antigen is a human platelet antigen (HPA), preferably selected from the group consisting of HPA-1, HPA-2, HPA-3, HPA-4, HPA-5, HPA6, HPA-9 and HPA-15.

19. The blood product according to any one of claims 15 to 18, wherein the PEG-phospholipid molecules, when anchored in the cell membrane of erythrocytes, have an average extracellular length selected in the interval of 4 nm to 8 nm, preferably 5 nm to 7 nm and more preferably 6 nm.

20. The blood product according to any one of claims 15 to 19, wherein the PEG-phospholipid molecule has formula (I): in n, m are independently selected from integers in the range of 10 to 16, preferably, n, m are independently 10, 12, 14 or 16, and more preferably, n=m=14; p is selected so that the PEG chains have an average molecular weight selected in the range of 3000 to 10000 Da and more preferably 5000 Da; and R is selected from the group consisting of H, methyl and C1-C4 alkylamine.

21. The blood product according to any one of claims 15 to 20, wherein the PEG-phospholipid molecules have an average molecular weight determined by gel permeation chromatography selected in the interval of 5 to 7 kDa, preferably 5.5 to 6.6 kDa and more preferably 5.8 to 6.0 kDa.

22. The blood product according to any one of claims 15 to 21, wherein the lipid portion of the PEG-phospholipid molecule is 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (DPPE).

23. The blood product according to any one of claims 15 to 22, wherein the PEG portion of the PEG-phospholipid molecule has an average degree of polymerization selected in the interval of 105 to 125, preferably in the interval of 110 to 120 and more preferably in the interval of 114 to 116.

24. The blood product according to any one of claims 15 to 23, wherein the PEG-phospholipid molecule is N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.

25. The blood product according to any one of claims 15 to 24, wherein the PEG-phospholipid molecules are not interconnected with other PEG-phospholipid molecules via any linker.

26. An in vitro method for treating red blood cells and / or platelets, the method comprising selectively masking surface antigens of red blood cells and / or platelets by adding in vitro poly(ethylene glycol)-lipid (PEG-phospholipid) molecules to the red blood cells and / or platelets, wherein the PEG chains of the PEG-phospholipid molecules have an average molecular weight selected in the range of 3000 to 10000 Da.

27. A blood transfusion method, the method comprising: adding poly(ethylene glycol)-lipid (PEG-phospholipid) molecules to a blood product from a donor to selectively mask surface antigens on red blood cells and / or platelets present in the blood product, wherein the PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3000 to 10000 Da; and The blood product is transfused into an uncrossmatched or incompatible recipient.

28. A method for screening irregular antibodies, the method comprising: adding PEG-phospholipid molecules to a blood sample of a subject to selectively mask surface antigens on red blood cells present in the blood sample, wherein the PEG chains of the PEG-phospholipid molecules have an average molecular weight selected within the range of 3,000 to 10,000 Da; and Screening for irregular antibodies that bind to red blood cells present in or obtained from said blood sample.

29. The method according to any one of claims 26 to 28, wherein the PEG-phospholipid molecule has formula (I): in n, m are independently selected from integers in the range of 10 to 16, preferably, n, m are independently 10, 12, 14 or 16, and more preferably, n=m=14; p is selected so that the PEG chains have an average molecular weight selected in the range of 3000 to 10000 Da and more preferably 5000 Da; and R is selected from the group consisting of H, methyl and C1-C4 alkylamine.

30. The method of claim 29, wherein the PEG-phospholipid molecule is N-(methylpolyoxyethyleneoxycarbonyl)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine.